GAVI Alliance

Annual Progress Report 2014

Submitted by

The Government of

Gambia

Reporting on year: **2014**
Requesting for support year: **2016**
Date of submission: **12/05/2015**

Deadline for submission: 15/05/2015

Please submit the APR 2014 using the online platform https://AppsPortal.gavialliance.org/PDExtranet

Enquiries to: apr@gavi.org or representatives of a GAVI Alliance partner. The documents can be shared with GAVI Alliance partners, collaborators and general public. The APR and attachments must be submitted in English, French, Spanish, or Russian.

Note: *You are encouraged to use previous APRs and approved Proposals for GAVI support as reference documents. The electronic copy of the previous APRs and approved proposals for GAVI support are available at* http://www.gavialliance.org/country/

The GAVI Secretariat is unable to return submitted documents and attachments to countries. Unless otherwise specified, documents will be shared with the GAVI Alliance partners and the general public.

GAVI ALLIANCE
GRANT TERMS AND CONDITIONS

FUNDING USED SOLELY FOR APPROVED PROGRAMMES

The applicant country ("Country") confirms that all funding provided by the GAVI Alliance will be used and applied for the sole purpose of fulfilling the programme(s) described in the Country's application. Any significant change from the approved programme(s) must be reviewed and approved in advance by the GAVI Alliance. All funding decisions for the application are made at the discretion of the GAVI Alliance Board and are subject to the Independent Review Committee (IRC) and its processes and the availability of funds.

AMENDMENT TO THE APPLICATION

The Country will notify the GAVI Alliance in its Annual Progress Report (APR) if it wishes to propose any change to the programme(s) description in its application. The GAVI Alliance will document any change approved by the GAVI Alliance, and the Country's application will be amended.

RETURN OF FUNDS

The Country agrees to reimburse to the GAVI Alliance all funding amounts that are not used for the programme(s) described in its application. The country's reimbursement must be in US dollars and be provided, unless otherwise decided by the GAVI Alliance, within sixty (60) days after the Country receives the GAVI Alliance's request for a reimbursement and be paid to the account or accounts as directed by the GAVI Alliance.

SUSPENSION/ TERMINATION

The GAVI Alliance may suspend all or part of its funding to the Country if it has reason to suspect that funds have been used for purpose other than for the programmes described in the Country's application, or any GAVI Alliance-approved amendment to the application. The GAVI Alliance retains the right to terminate its support to the Country for the programmes described in its application if a misuse of GAVI Alliance funds is confirmed.

ANTICORRUPTION

The Country confirms that funds provided by the GAVI Alliance shall not be offered by the Country to any third person, nor will the Country seek in connection with its application any gift, payment or benefit directly or indirectly that could be construed as an illegal or corrupt practice.

AUDITS AND RECORDS

The Country will conduct annual financial audits, and share these with the GAVI Alliance, as requested. The GAVI Alliance reserves the right, on its own or through an agent, to perform audits or other financial management assessment to ensure the accountability of funds disbursed to the Country.

The Country will maintain accurate accounting records documenting how GAVI Alliance funds are used. The Country will maintain its accounting records in accordance with its government-approved accounting standards for at least three years after the date of last disbursement of GAVI Alliance funds. If there is any claims of misuse of funds, Country will maintain such records until the audit findings are final. The Country agrees not to assert any documentary privilege against the GAVI Alliance in connection with any audit.

CONFIRMATION OF LEGAL VALIDITY

The Country and the signatories for the Country confirm that its application, and APR, are accurate and correct and form legally binding obligations on the Country, under the Country's law, to perform the programmes described in its application, as amended, if applicable, in the APR.

CONFIRMATION OF COMPLIANCE WITH THE GAVI ALLIANCE TRANSPARANCY AND ACCOUNTABILITY POLICY

The Country confirms that it is familiar with the GAVI Alliance Transparency and Accountability Policy (TAP) and complies with the requirements therein.

USE OF COMMERCIAL BANK ACCOUNTS

The Country is responsible for undertaking the necessary due diligence on all commercial banks used to manage GAVI cash-based support. The Country confirms that it will take all responsibility for replenishing GAVI cash support lost due to bank insolvency, fraud or any other unforeseen event.

ARBITRATION

Any dispute between the Country and the GAVI Alliance arising out of or relating to its application that is not settled amicably within a reasonable period of time, will be submitted to arbitration at the request of either the GAVI Alliance or the Country. The arbitration will be conducted in accordance with the then-current UNCITRAL Arbitration Rules. The parties agree to be bound by the arbitration award, as the final adjudication of any such dispute. The place of arbitration will be Geneva, Switzerland. The languages of the arbitration will be English or French.

For any dispute for which the amount at issue is US$ 100,000 or less, there will be one arbitrator appointed by the GAVI Alliance. For any dispute for which the amount at issue is greater than US $100,000 there will be three arbitrators appointed as follows: The GAVI Alliance and the Country will each appoint one arbitrator, and the two arbitrators so appointed will jointly appoint a third arbitrator who shall be the chairperson.

The GAVI Alliance will not be liable to the country for any claim or loss relating to the programmes described in the application, including without limitation, any financial loss, reliance claims, any harm to property, or personal injury or death. Country is solely responsible for all aspects of managing and implementing the programmes described in its application.

By filling this APR the country will inform GAVI about:

Accomplishments using GAVI resources in the past year

Important problems that were encountered and how the country has tried to overcome them

Meeting accountability needs concerning the use of GAVI disbursed funding and in-country arrangements with development partners

Requesting more funds that had been approved in previous application for ISS/NVS/HSS, but have not yet been released

How GAVI can make the APR more user-friendly while meeting GAVI's principles to be accountable and transparent.

1. Application Specification

Reporting on year: **2014**

Requesting for support year: **2016**

1.1. NVS & INS support

Type of Support	Current Vaccine	Preferred presentation	Active until
Routine New Vaccines Support	Measles second dose, 10 dose(s) per vial, LYOPHILISED	Measles second dose, 10 dose(s) per vial, LYOPHILISED	2016
Routine New Vaccines Support	Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	2015
Routine New Vaccines Support	DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	2015
Routine New Vaccines Support	Rotavirus, 3-dose schedule	Rotavirus, 3-dose schedule	2016
Routine New Vaccines Support	IPV, 10 dose(s) per vial, LIQUID	IPV, 10 dose(s) per vial, LIQUID	2018

DTP-HepB-Hib (Pentavalent) vaccine: Based on current country preferences the vaccine is available through UNICEF in fully liquid 1 and 10 dose vial presentations and in a 2 dose-2 vials liquid/lyophilised formulation, to be used in a three-dose schedule. Other presentations are also WHO pre-qualified, and a full list can be viewed on the WHO website, but availability would need to be confirmed specifically.

IPV second preferred presentation: **IPV, 5 dose(s) per vial, LIQUID**

IPV third preferred presentation: **IPV, 1 dose(s) per vial, LIQUID**

1.2. Programme extension

Type of Support	Vaccine	Start year	End year
Routine New Vaccines Support	Measles second dose, 10 dose(s) per vial, LYOPHILISED	2017	2017
Routine New Vaccines Support	Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	2016	2020
Routine New Vaccines Support	DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	2016	2020
Routine New Vaccines Support	Rotavirus, 3-dose schedule	2017	2020
Routine New Vaccines Support	IPV, 10 dose(s) per vial, LIQUID	2019	2020

1.3. ISS, HSS, CSO support

Type of Support	Reporting fund utilisation in 2014	Request for Approval of	Eligible For 2014 ISS reward
VIG	Yes	Not applicable	No
HSS	Yes	next tranche of HSS Grant Yes	No

VIG: Vaccine Introduction Grant; COS: Campaign Operational Support

1.4. Previous Monitoring IRC Report

APR Monitoring IRC Report for year 2013 is available here.

2. Signatures

2.1. Government Signatures Page for all GAVI Support (ISS, INS, NVS, HSS, CSO)

By signing this page, the Government of Gambia hereby attests the validity of the information provided in the report, including all attachments, annexes, financial statements and/or audit reports. The Government further confirms that vaccines, supplies, and funding were used in accordance with the GAVI Alliance Standard Grant Terms and Conditions as stated in this Annual Progress Report (APR).

For the Government of Gambia

Please note that this APR will not be reviewed or approved by the High Level Review Panel (HLRP) without the signatures of both the Minister of Health & Minister Finance or their delegated authority.

Minister of Health (or delegated authority)		Minister of Finance (or delegated authority)	
Name	Honourable Omar Sey	**Name**	Honourable Abdou Kolley
Date		**Date**	
Signature		**Signature**	

This report has been compiled by (these persons may be contacted in case the GAVI Secretatiat has queries on this document):

Full name	Position	Telephone	Email
Mr. Dawda Sowe	Programme Manager - EPI	+220 6722539	dmsowe@yahoo.co.uk
Mr. Kebba M.S. Gibba	NPO - EPI	+220 6540758	gibbak@who.int
Mr. Baboucarr Boye	Immunisation Specialist	+220 3360087	bboye@unicef.org

2.2. ICC signatures page

If the country is reporting on Immunisation Services (ISS), Injection Safety (INS) and/or New and Under-Used Vaccines (NVS) supports

In some countries, HSCC and ICC committees are merged. Please fill-in each section where information is appropriate and upload in the attached documents section the signatures twice, one for HSCC signatures and one for ICC signatures

The GAVI Alliance Transparency and Accountability Policy (TAP) is an integral part of GAVI Alliance monitoring of country performance. By signing this form the ICC members confirm that the funds received from the GAVI Alliance have been used for purposes stated within the approved application and managed in a transparent manner, in accordance with government rules and regulations for financial management.

2.2.1. ICC report endorsement

We, the undersigned members of the immunisation Inter-Agency Coordinating Committee (ICC), endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Name/Title	Agency/Organization	Signature	Date
Dr. Makie TAAL - Permanent Secretary	Ministry of Health and Social Welfare		

Dr. Samba CEESAY - Ag. Director of Health Services	Ministry of Health and Social Welfare		
Dr. Charles SAGOE-MOSES - Country Representative	World Health Organization		
Mr. Rupert LEIGHTON - Deputy Representative and OIC	UNICEF		
Mr. Bolong S. JOBARTEH - Chief Public Health Officer	Ministry of Health and Social Welfare		
Ms. Fatou GAYE - Ag. Secretary General	The Gambia Red Cross Society		
Mrs. Adam WADDA-JAMMEH - President Rotary Club of Fajara	Rotary International		
Mr. James Muwanga PIMUNDU - Country Director	Child Fund - The Gambia		
Mr. Omar BADJIE - Country Director	Action Aid International - The Gambia		
Prof. D'Alessandro UMBERTO - Unit Director	Medical Research Council - The Gambia		
Mr. Modou NJAI - Director of Health Promotion and Education	Ministry of Health and Social Welfare		
Mr. Sanna SAMBOU - Coordinator Epidemiology and Disease Surveillance	Ministry of Health and Social Welfare		
Mr. Bafoday JAWARA - Head Reproductive and Child Health	Ministry of Health and Social Welfare		
Mr. Janko JIMBARA - Director of Human Resource	Ministry of Health and Social Welfare		

Mr. Omar Bun NJIE - Director of Planning and Information	Ministry of Health and Social Welfare		
Mr. Modou Cheyassin PHALL - Executive Director	National Nutrition Agency		
Mrs. Theresse DRAMMEH - Director	Riders for Health		
Mr. Omar Malleh CEESAY - Director	Health Promotion and development Organisation (HePDO)		
Mr. Ebrima JARJU - Head of Programmes	Catholic Relief Services		
Mr. Alhagie SANKAREH - Regional Health Director Western 1	Ministry of Health and Social Welfare		
Mr. Ngally Abubacarr SAMBOU - Regional Health Director Western 2	Ministry of Health and Social Welfare		

ICC may wish to send informal comments to: apr@gavi.org

All comments will be treated confidentially

Comments from Partners:

Comments from the Regional Working Group:

2.3. HSCC signatures page

We, the undersigned members of the National Health Sector Coordinating Committee (HSCC), No HSCC , endorse this report on the Health Systems Strengthening Programme. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

The GAVI Alliance Transparency and Accountability Policy is an integral part of GAVI Alliance monitoring of country performance. By signing this form the HSCC members confirm that the funds received from the GAVI Alliance have been used for purposes stated within the approved application and managed in a transparent manner, in accordance with government rules and regulations for financial management. Furthermore, the HSCC confirms that the content of this report has been based upon accurate and verifiable financial reporting.

Name/Title	Agency/Organization	Signature	Date
NO HSCC	NO AGENCY		

HSCC may wish to send informal comments to: apr@gavi.org

All comments will be treated confidentially

Comments from Partners:

No HSCC in the Gambia

Comments from the Regional Working Group:

No HSCC in theGambia

2.4. Signatures Page for GAVI Alliance CSO Support (Type A & B)

Gambia is not reporting on CSO (Type A & B) fund utilisation in 2015

3. Table of Contents

This APR reports on Gambia's activities between January – December 2014 and specifies the requests for the period of January – December 2016

Sections

4. Baseline & annual targets

Countries are encouraged to aim for realistic and appropriate wastage rates informed by an analysis of their own wastage data. In the absence of country-specific data, countries may use indicative maximum wastage values as shown on the **Wastage Rate Table** available in the guidelines. Please note the benchmark wastage rate for 10ds pentavalent which is available.

Please also note that if the country applies the WHO multi-dose vial policy for IPV, the maximum indicative wastage rates are 5%, 15% and 20% for the 1-dose, 5-dose and 10-dose presentations respectively.

Number	Achievements as per JRF		Targets (preferred presentation)							
	2014		2015		2016		2017		2018	
	Original approved target according to Decision Letter	Reported	Original approved target according to Decision Letter	Current estimation	Previous estimates in 2014	Current estimation	Previous estimates in 2014	Current estimation	Previous estimates in 2014	Current estimation
Total births	84,039	84,039	86,308	86,308	88,639	88,639		90,678		92,763
Total infants' deaths	6,219	6,219	6,387	6,387	6,648	6,648		6,801		6,957
Total surviving infants	77820	77,820	79,921	79,921	81,991	81,991		83,877		85,806
Total pregnant women	77,820	77,820	79,921	79,921	82,080	82,080		84,542		87,079
Number of infants vaccinated (to be vaccinated) with BCG	80,678	80,407	84,582	84,582	87,753	87,753		89,771		91,835
BCG coverage*[1]*	96 %	96 %	98 %	98 %	99 %	99 %	0 %	99 %	0 %	99 %
Number of infants vaccinated (to be vaccinated) with OPV3	77,042	75,564	79,122	79,122	81,171	81,171		83,038		84,948
OPV3 coverage*[2]*	99 %	97 %	99 %	99 %	99 %	99 %	0 %	99 %	0 %	99 %
Number of infants vaccinated (to be vaccinated) with DTP1*[3]*	77,821	76,056	79,122	79,122	81,171	81,171		83,038		84,948
Number of infants vaccinated (to be vaccinated) with DTP3*[3][4]*	77,042	74,509	79,122	79,122	81,171	81,171		83,038		84,948
DTP3 coverage*[2]*	99 %	96 %	99 %	99 %	99 %	99 %	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%) for DTP	5	5	5	5	5	5		4		4
Wastage*[5]* factor in base-year and planned thereafter for DTP	1.05	1.05	1.05	1.05	1.05	1.05	1.00	1.04	1.00	1.04
Number of infants vaccinated (to be vaccinated) with 1st dose of DTP-HepB-Hib	77,821	76,056	79,122	79,122		81,171		83,038		84,948
Number of infants vaccinated (to be vaccinated) with 3rd dose of DTP-HepB-Hib	77,821	74,509	79,122	79,122		81,171		83,038		84,948
DTP-HepB-Hib coverage*[2]*	100 %	96 %	99 %	99 %	0 %	99 %	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%) *[6]*	15	15	10	10		10		10		8
Wastage*[5]* factor in base-year and planned thereafter (%)	1.18	1.18	1.11	1.11	1	1.11	1	1.11	1	1.09
Maximum wastage rate value for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	0 %	0 %	0 %	25 %	0 %	25 %	0 %	25 %	0 %	25 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Pneumococcal (PCV13)	77,042	75,899	79,122	79,122		81,171		83,038		84,948

Number of infants vaccinated (to be vaccinated) with 3rd dose of Pneumococcal (PCV13)	77,042	74,467	79,122	79,122		81,171		83,038		84,948
Pneumococcal (PCV13) coverage*[2]*	99 %	96 %	99 %	99 %	0 %	99 %	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%)	5	5	5	5		5		4		4
Wastage*[5]* factor in base-year and planned thereafter (%)	1.05	1.05	1.05	1.05	1	1.05	1	1.04	1	1.04
Maximum wastage rate value for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	0 %	5 %	0 %	5 %	0 %	5 %	0 %	5 %	0 %	5 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Rotavirus	72,373	74,640	79,122	79,122	81,171	81,171		83,038		84,948
Number of infants vaccinated (to be vaccinated) with 3rd dose of Rotavirus	72,373	71,540	79,122	79,122	81,171	81,171		83,038		84,948
Rotavirus coverage*[2]*	93 %	92 %	99 %	99 %	99 %	99 %	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%)	5	5	5	5	5	5		5		4
Wastage*[5]* factor in base-year and planned thereafter (%)	1.05	1.05	1.05	1.05	1.05	1.05	1	1.05	1	1.04
Maximum wastage rate value for Rotavirus, 3-dose schedule	0 %	5 %	0 %	5 %	0 %	5 %	0 %	5 %	0 %	5 %
Number of infants vaccinated (to be vaccinated) with IPV		0	77,017	79,122	78,752	81,171		83,038		84,948
Wastage*[5]* rate in base-year and planned thereafter (%)		0	50	50	50	50		50		50
Wastage*[5]* factor in base-year and planned thereafter (%)	1	1	2	2	2	2	1	2	1	2
Maximum wastage rate value for IPV, 10 dose(s) per vial, LIQUID (see note above)	0 %	50 %	0 %	50 %	0 %	50 %	0 %	50 %	0 %	50 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Measles	0	74,643	75,926	75,926	77,072	77,072		79,683		81,516
Number of infants vaccinated (to be vaccinated) with 2nd dose of Measles	73,152	56,887	75,926	75,926	77,072	77,072		79,683		81,516
Measles coverage*[2]*	94 %	73 %	95 %	95 %	94 %	94 %	0 %	95 %	0 %	95 %
Wastage*[5]* rate in base-year and planned thereafter (%)	13	13	12	12	12	12		12		12
Wastage*[5]* factor in base-year and planned thereafter (%)	1.15	1.15	1.14	1.14	1.14	1.14	1	1.14	1	1.14
Maximum wastage rate value for Measles second dose, 10 dose(s) per vial, LYOPHILISED	0.00 %	40.00 %	0.00 %	40.00 %	0.00 %	40.00 %	0.00 %	40.00 %	0.00 %	40.00 %
Pregnant women vaccinated with TT+	61,478	50,124	63,937	63,937	69,692	69,692		77,076		78,849
TT+ coverage*[7]*	79 %	64 %	80 %	80 %	85 %	85 %	0 %	91 %	0 %	91 %
Vit A supplement to mothers within 6 weeks from delivery	0	0	0	0	0	0		0		0
Vit A supplement to infants after 6 months	0	0	0	0	0	0	N/A	0	N/A	0

Annual DTP Drop out rate [(DTP1 – DTP3) / DTP1] x 100	1 %	2 %	0 %	0 %	0 %	0 %	0 %	0 %	0 %	0 %

Number	**Targets (preferred presentation)**			
	2019		**2020**	
	Previous estimates in 2014	Current estimation	Previous estimates in 2014	Current estimation
Total births		95,546		98,412
Total infants' deaths		7,166		7,381
Total surviving infants		88,380		91,031
Total pregnant women		89,691		92,382
Number of infants vaccinated (to be vaccinated) with BCG		94,590		97,428
BCG coverage*[1]*	0 %	99 %	0 %	99 %
Number of infants vaccinated (to be vaccinated) with OPV3		87,496		90,121
OPV3 coverage*[2]*	0 %	99 %	0 %	99 %
Number of infants vaccinated (to be vaccinated) with DTP1*[3]*		87,496		90,121
Number of infants vaccinated (to be vaccinated) with DTP3*[3][4]*		87,496		90,121
DTP3 coverage*[2]*	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%) for DTP		4		4
Wastage*[5]* factor in base-year and planned thereafter for DTP	1.00	1.04	1.00	1.04
Number of infants vaccinated (to be vaccinated) with 1st dose of DTP-HepB-Hib		87,496		90,121
Number of infants vaccinated (to be vaccinated) with 3rd dose of DTP-HepB-Hib		87,496		90,121
DTP-HepB-Hib coverage*[2]*	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%) *[6]*		8		8
Wastage*[5]* factor in base-year and planned thereafter (%)	1	1.09	1	1.09
Maximum wastage rate value for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	0 %	25 %	0 %	25 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Pneumococcal (PCV13)		87,496		90,121
Number of infants vaccinated (to be vaccinated) with 3rd dose of Pneumococcal (PCV13)		87,496		90,121
Pneumococcal (PCV13) coverage*[2]*	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%)		4		4
Wastage*[5]* factor in base-year and planned thereafter	1	1.04	1	1.04

(%)				
Maximum wastage rate value for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	0 %	5 %	0 %	5 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Rotavirus		87,496		90,121
Number of infants vaccinated (to be vaccinated) with 3rd dose of Rotavirus		87,496		90,121
Rotavirus coverage*[2]*	0 %	99 %	0 %	99 %
Wastage*[5]* rate in base-year and planned thereafter (%)		4		4
Wastage*[5]* factor in base-year and planned thereafter (%)	1	1.04	1	1.04
Maximum wastage rate value for Rotavirus, 3-dose schedule	0 %	5 %	0 %	5 %
Number of infants vaccinated (to be vaccinated) with IPV		87,496		90,121
Wastage*[5]* rate in base-year and planned thereafter (%)		40		40
Wastage*[5]* factor in base-year and planned thereafter (%)	1	1.67	1	1.67
Maximum wastage rate value for IPV, 10 dose(s) per vial, LIQUID (see note above)	0 %	50 %	0 %	50 %
Number of infants vaccinated (to be vaccinated) with 1st dose of Measles		83,961		86,480
Number of infants vaccinated (to be vaccinated) with 2nd dose of Measles		83,961		86,480
Measles coverage*[2]*	0 %	95 %	0 %	95 %
Wastage*[5]* rate in base-year and planned thereafter (%)		12		12
Wastage*[5]* factor in base-year and planned thereafter (%)	1	1.14	1	1.14
Maximum wastage rate value for Measles second dose, 10 dose(s) per vial, LYOPHILISED	0.00 %	40.00 %	0.00 %	40.00 %
Pregnant women vaccinated with TT+		81,214		83,650
TT+ coverage*[7]*	0 %	91 %	0 %	91 %
Vit A supplement to mothers within 6 weeks from delivery		0		0
Vit A supplement to infants after 6 months	N/A	0	N/A	0
Annual DTP Drop out rate [(DTP1 – DTP3) / DTP1] x 100	0 %	0 %	0 %	0 %

[1] Number of infants vaccinated out of total births

[2] Number of infants vaccinated out of total surviving infants

[3] Indicate total number of children vaccinated with either DTP alone or combined

[4] Please make sure that the DTP3 cells are correctly populated

[5] The formula to calculate a vaccine wastage rate (in percentage): [(A – B) / A] x 100. Whereby: A = the number of doses distributed for use according to the supply records with correction for stock balance at the end of the supply period; B = the number of vaccinations with the same vaccine in the same period.

[6] GAVI would also appreciate feedback from countries on feasibility and interest of selecting and being shipped multiple Pentavalent vaccine presentations (1 dose and 10 dose vials) so as to optimise wastage, coverage and cost.

[7] Number of pregnant women vaccinated with TT+ out of total pregnant women

5. General Programme Management Component

5.1. Updated baseline and annual targets

Note: Fill in the table in section 4 Baseline and Annual Targets before you continue

The numbers for 2014 must be consistent with those that the country reported in the **WHO/UNICEF Joint Reporting Form (JRF) for 2014.** The numbers for 2015 - 2016 in Table 4 Baseline and Annual Targets should be consistent with those that the country provided to GAVI in previous APR or in new application for GAVI support or in cMYP.

In fields below, please provide justification and reasons for those numbers that in this APR are different from the referenced ones:

- Justification for any changes in **births**

  No changes effected in the number of live births for The Gambia for 2014. The figures remain the same as those provided to GAVI in 2013.

- Justification for any changes in **surviving infants**

  There are no changes in the number of surviving infants in The Gambia in 2014. The figures are the same as the ones provided to GAVI in 2013.

- Justification for any changes in targets by vaccine. **Please note that targets in excess of 10% of previous years' achievements will need to be justified.** For IPV, supporting documentation must also be provided as an attachment(s) to the APR to justify ANY changes in target population.

  No changes, the targets remain the same as those reported in the 2013 APR.

- Justification for any changes in **wastage by vaccine**

  There are no changes in vaccine wastage factors. The wastage figures remains the same for both years.

5.2. Monitoring the Implementation of GAVI Gender Policy

5.2.1. At any point in the past five years, were sex-disaggregated data on DTP3 coverage available in your country from administrative data sources and/or surveys? **yes, available**

If yes, please report the latest data available and the year that it is from.

Data Source	Reference Year for Estimate	DTP3 Coverage Estimate	
		Boys	Girls
GDHS 2013	2013	89%	86%

5.2.2. How have any discrepancies in reaching boys versus girls been addressed programmatically?

There is no gender barrier to immunization services in The Gambia.

5.2.3. If no sex-disaggregated data are available at the moment, do you plan in the future to collect sex-disaggregated coverage estimates? **Yes**

5.2.4. How have any gender-related barriers to accessing and delivering immunisation services (eg, mothers not being empowered to access services, the sex of service providers, etc) been addressed programmatically ? (For more information on gender-related barriers, please see GAVI's factsheet on gender and immunisation, which can be found on http://www.gavialliance.org/about/mission/gender/)

There is no gender barrier to immunisation services in The Gambia

5.3. Overall Expenditures and Financing for Immunisation

The purpose of **Table 5.3a** is to guide GAVI understanding of the broad trends in immunisation programme expenditures and financial flows. Please fill the table using US$.

Exchange rate used	1 US$ = 40	Enter the rate only; Please do not enter local currency name

Table 5.3a: Overall Expenditure and Financing for Immunisation from all sources (Government and donors) in US$

Expenditure by category	**Expenditure Year 2014**	**Source of funding**						
		Country	**GAVI**	**UNICEF**	**WHO**	**Action Aid**	**Social Security**	**Gamcel**
Traditional Vaccines*	401,210	401,210	0	0	0	0	0	0
New and underused Vaccines**	2,224,725	155,000	2,069,725	0	0	0	0	0
Injection supplies (both AD syringes and syringes other than ADs)	761,385	36,110	725,275	0	0	0	0	0
Cold Chain equipment	81,200	1,200	0	80,000	0	0	0	0
Personnel	22,972	22,972	0	0	0	0	0	0
Other routine recurrent costs	14,821	12,190	2,631	0	0	0	0	0
Other Capital Costs	100,000	0	0	0	100,000	0	0	0
Campaigns costs	839,366	250,000	0	203,866	375,000	8,750	1,250	500
Effective Vaccine Management		0	0	70,000	0	0	0	0
Total Expenditures for Immunisation	4,445,679							
Total Government Health		878,682	2,797,631	353,866	475,000	8,750	1,250	500

Traditional vaccines: BCG, DTP, OPV, Measles 1st dose (or the combined MR, MMR), TT. Some countries will also include HepB and Hib vaccines in this row, if these vaccines were introduced without GAVI support

5.4. Interagency Coordinating Committee (ICC)

How many times did the ICC meet in 2014? **4**

Please attach the minutes **(Document nº 4)** from the ICC meeting in 2015 endorsing this report.

List the key concerns or recommendations, if any, made by the ICC on sections 5.1 Updated baseline and annual targets to 5.3 Overall Expenditures and Financing for Immunisation

ICC recommended for the increase of government budget allocation for vaccines which resulted in the increase from GMD23,000,000.00 to GMD24,000,000.00 in 2014 financial year.

ICC recommended for the building of an EPI office with a dry store to house injection materials.

ICC recommended the EPI to apply for new vaccine introduction (IPV, MR Preventive campaign and HSS)

Are any Civil Society Organisations members of the ICC? **Yes**

If Yes, which ones?

List CSO member organisations:
Child Fund - The Gambia
Action Aid - The Gambia
The Gambia Red Cross Society
Rotary International
Catholic Relief Services (CRS)
Health Promotion and Development Organisation (HePDO)

5.5. Priority actions in 2015 to 2016

What are the country's main objectives and priority actions for its EPI programme for 2015 to 2016

The main objectives of the EPI for 2015 - 2016 includes
1. To build the capacity of health staff on immunisation services
2. To conduct EPI cluster survey to validate the administrative data
3. To increase immunisation coverage by raising awareness of Gambians on the benefits of immunisation
4. To ensure sustainable supply and safety of vaccines and consumables
5. To introduce new vaccines, technologies and policies in a sustainable manner
6. To reduce immunisation drop-out and wastage rates to below 2% and 5% respectively

The main priorities of the EPI for 2015- 2016 include
1. Strengthening immunisation services (training, retraining, expanding outreach services, strengthening supportive supervision)
2. Improving surveillance and accelerated disease prevention and control (eradication and elimination of vaccine preventable diseases)
3. Advocating for increased financial commitment
4. Conducting operational research and other relevant technologies in relation to immunization services
5. Introducing new vaccines into the routine immunization services
6. Strengthening GPEI activities

7. Increasing community involvement and participation

5.6. Progress of transition plan for injection safety

For all countries, please report on progress of transition plan for injection safety

Please report what types of syringes are used and the funding sources of Injection Safety material in 2014

Vaccine	Types of syringe used in 2014 routine EPI	Funding sources of 2014
BCG	0.05 ml	Government
Measles	0.5ml	Government
TT	0.5ml	Government
DTP-containing vaccine	0.5ml	Government
IPV	0.5ml	GAVI
HepB Mono Birth Dose	0.5ml	Government
Yellow Fever	0.5ml	Government

Does the country have an injection safety policy/plan? **Yes**

If Yes: Have you encountered any obstacles during the implementation of this injection safety policy/plan?

If No: When will the country develop the injection safety policy/plan? (Please report in box below)

The country does not have a stand-alone injection policy. However, safe injection practices form an integral part of the EPI training manuals, which have been revised and given due attention during EPI trainings.

Please explain in 2014 how sharps waste is being disposed of, problems encountered, etc.

An incinerator has been built in each of the 7 health regions exclusively for the management of sharp wastes. Sharps are initially disposed of in safety boxes at the site of injection and are later transported to the incineration sites. There are incinerator attendants in each region for the management of sharp waste under the supervision of the regional health team. Quarterly incentives are provided to the incinerator attendants for their up keep.

6. Immunisation Services Support (ISS)

6.1. Report on the use of ISS funds in 2014

Gambia is not reporting on Immunisation Services Support (ISS) fund utilisation in 2014

6.2. Detailed expenditure of ISS funds during the 2014 calendar year

Gambia is not reporting on Immunisation Services Support (ISS) fund utilisation in 2014

6.3. Request for ISS reward

Request for ISS reward achievement in Gambia is not applicable for 2014

7. New and Under-used Vaccines Support (NVS)

7.1. Receipt of new & under-used vaccines for 2014 vaccine programme

7.1.1. Did you receive the approved amount of vaccine doses for 2014 Immunisation Programme that GAVI communicated to you in its Decision Letter (DL)? Fill-in table below

Table 7.1: Vaccines received for 2014 vaccinations against approvals for 2014

Please also include any deliveries from the previous year received against this Decision Letter

	[A]	[B]	[C]	
Vaccine type	**Total doses for 2014 in Decision Letter**	**Total doses received by 31 December 2014**	**Total doses postponed from previous years and received in 2014**	**Did the country experience any stockouts at any level in 2014?**
Measles second dose	118,200	118,200	0	No
Pneumococcal (PCV13)	245,000	245,000	0	No
DTP-HepB-Hib	375,900	375,900	0	No
Rotavirus	230,500	119,350	111,150	No
IPV		0	0	No

If values in [A] and [B] are different, specify:

- What are the main problems encountered? (Lower vaccine utilisation than anticipated due to delayed new vaccine introduction or lower coverage? Delay in shipments? Stock-outs? Excessive stocks? Problems with cold chain? Doses discarded because VVM changed colour or because of the expiry date? ...)

  All the planned shipments for 2014 were received except one shipment for Rota due to inadequate cold chain storage capacity. The Gambia uses Rota Teq which has a high pack volume. This could not all be accommodated within the national cold chain capacity with other vaccines which resulted in delay in receiving the last shipment of Rota.

- What actions have you taken to improve the vaccine management, e.g. such as adjusting the plan for vaccine shipments? (in the country and with UNICEF Supply Division)

  GAVI would also appreciate feedback from countries on feasibility and interest of selecting and being shipped multiple Pentavalent vaccine presentations (1 dose and 10 dose vials) so as to optimise wastage, coverage and cost.

  The country conducts physical count at national level. If the stock is below the critical level (less than three months needs), then UNICEF Supply Division is requested to send shipments in advance.

If **Yes** for any vaccine in **Table 7.1**, please describe the duration, reason and impact of stock-out, including if the stock-out was at the central, regional, district or at lower facility level.

No stock-out.

7.2. Introduction of a New Vaccine in 2014

7.2.1. If you have been approved by GAVI to introduce a new vaccine in 2014, please refer to the vaccine introduction plan in the proposal approved and report on achievements:

DTP-HepB-Hib, 10 dose(s) per vial, LIQUID		
Nationwide introduction	No	01/08/2009
Phased introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	Yes	Nil

When is the Post Introduction Evaluation (PIE) planned? **September 2010**

IPV, 10 dose(s) per vial, LIQUID		
Nationwide introduction	Yes	01/04/2015
Phased introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	Yes	Nil

When is the Post Introduction Evaluation (PIE) planned? **October 2016**

Measles second dose, 10 dose(s) per vial, LYOPHILISED		
Nationwide introduction	Yes	01/08/2012
Phased introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	Yes	Nil

When is the Post Introduction Evaluation (PIE) planned? **May 2015**

Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID		
Nationwide introduction	Yes	01/04/2009
Phased introduction	No	
The time and scale of introduction was as planned in the proposal? If No, Why ?	Yes	Nil

When is the Post Introduction Evaluation (PIE) planned? **October 2010**

Rotavirus, 1 dose(s) per vial, ORAL		
Nationwide introduction	Yes	01/08/2013
Phased introduction	No	
The time and scale of	Yes	Nil

introduction was as planned in the proposal? If No, Why ?		

When is the Post Introduction Evaluation (PIE) planned? **October 2015**

7.2.2. If your country conducted a PIE in the past two years, please attach relevant reports and provide a summary on the status of implementation of the recommendations following the PIE. (Document N° 9))

The last PIE conducted in The Gambia was in 2010 for the PCV which was introduced in the Routine Immunisation in 2009.

7.2.3. Adverse Event Following Immunization (AEFI)

Is there a national dedicated vaccine pharmacovigilance capacity? **No**

Is there a national AEFI expert review committee? **No**

Does the country have an institutional development plan for vaccine safety? **No**

Is the country sharing its vaccine safety data with other countries? **No**

Does your country have a risk communication strategy with preparedness plans to address vaccine crises? **Yes**

7.2.4. Surveillance

Does your country conduct sentinel surveillance for:

a. rotavirus diarrhea? **Yes**

b. pediatric bacterial meningitis or pneumococcal or meningococcal disease? **Yes**

Does your country conduct special studies around:

a. rotavirus diarrhea? **Yes**

b. pediatric bacterial meningitis or pneumococcal or meningococcal disease? **Yes**

If so, does the National Immunization Technical Advisory Group (NITAG) or the Inter-Agency Coordinating Committee (ICC) regularly review the sentinel surveillance and special studies data to provide recommendations on the data generated and how to further improve data quality? **No**

Do you plan to use these sentinel surveillance and/or special studies data to monitor and evaluate the impact of vaccine introduction and use? **Yes**

Please describe the results of surveillance/special studies and inputs of the NITAG/ICC:

The country is conducting an ongoing sentinel surveillance on Rota Virus and is also planning to start Rota impact and intussusception study. This is being jointly coordinated by the National Public Health Laboratories, EPI and Edward Francis Small Teaching Hospital.

7.3. New Vaccine Introduction Grant lump sums 2014

7.3.1. Financial Management Reporting

	Amount US$	Amount local currency
Funds received during 2014 (A)	270,000	11,610,000
Remaining funds (carry over) from 2013 (B)	0	0
Total funds available in 2014 (C=A+B)	270,000	11,610,000
Total Expenditures in 2014 (D)	39,455	1,578,200
Balance carried over to 2015 (E=C-D)	230,545	10,031,800

Detailed expenditure of New Vaccines Introduction Grant funds during the 2014 calendar year

Please attach a detailed financial statement for the use of New Vaccines Introduction Grant funds in the 2014 calendar year (Document No 10,11) . Terms of reference for this financial statement are available in **Annexe 1** Financial statements should be signed by the Finance Manager of the EPI Program and and the EPI Manager, or by the Permanent Secretary of Ministry of Health

7.3.2. Programmatic Reporting

Please report on major activities that have been undertaken in relation to the introduction of a new vaccine, using the GAVI New Vaccine Introduction Grant

1. Training of health workers on HPV
2. Social Mobilisation on the HPV for service providers and communities
3. Document production
4. Monitoring and supervision
5. TAG meeting including advocacy
6. Launching
7. ICC Meetings

Please describe any problem encountered and solutions in the implementation of the planned activities

The major challenges encountered include
1. Reaching the out of school girls for the HPV demo was a challenge as there was no out of school census conducted to validate the target
2. The number of days for the vaccination was inadequate to reach the target population.
3. Recording, tallying and immunizing in populated schools was a major challenge
4. Delay in starting the ADH assessment

Measures taken to overcome the challenges include:
1. Out of school girls target population was projected based on school enrolment data from the Ministry of Basic and Secondary Education
2. Mop-up exercise was conducted.
3. School teachers were helping in some major schools
4. Unicef has been engaged to provide ADH consultant

Please describe the activities that will be undertaken with any remaining balance of funds for 2015 onwards

1. Mandatory Evaluations (ADH assessment, Post Introduction Evaluation, Costing Analysis and Cluster Survey)
2, Training and retraining of health care workers and communication mobilisation
3. Vaccination for the dose 2 of year 1 and dose 1&2 of year 2
4. Monitoring and evaluation
5. TAG meetings
6. Development of a cancer control strategic plan.

7. Document production

7.4. Report on country co-financing in 2014

Table 7.4 : Five questions on country co-financing

	Q.1: What were the actual co-financed amounts and doses in 2014?	
Co-Financed Payments	**Total Amount in US$**	**Total Amount in Doses**
Awarded Vaccine #1: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	75,500	36,800
Awarded Vaccine #2: IPV, 10 dose(s) per vial, LIQUID*	0	0

Awarded Vaccine #3: Measles second dose, 10 dose(s) per vial, LYOPHILISED	0	0
Awarded Vaccine #4: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	49,000	13,700
Awarded Vaccine #5: Rotavirus, 1 dose(s) per vial, ORAL	30,500	8,600
	Q.2: Which were the amounts of funding for country co-financing in reporting year 2014 from the following sources?	
Government	155000	
Donor	0	
Other	0	
	Q.3: Did you procure related injections supplies for the co-financing vaccines? What were the amounts in US$ and supplies?	
Co-Financed Payments	**Total Amount in US$**	**Total Amount in Doses**
Awarded Vaccine #1: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	0	0
Awarded Vaccine #2: IPV, 10 dose(s) per vial, LIQUID*	0	0
Awarded Vaccine #3: Measles second dose, 10 dose(s) per vial, LYOPHILISED	0	0
Awarded Vaccine #4: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	0	0
Awarded Vaccine #5: Rotavirus, 1 dose(s) per vial, ORAL	0	0
	Q.4: When do you intend to transfer funds for co-financing in 2016 and what is the expected source of this funding	
Schedule of Co-Financing Payments	Proposed Payment Date for 2016	Source of funding
Awarded Vaccine #1: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	August	Government
Awarded Vaccine #2: IPV, 10 dose(s) per vial, LIQUID*		
Awarded Vaccine #3: Measles second dose, 10 dose(s) per vial, LYOPHILISED		
Awarded Vaccine #4: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	August	Government
Awarded Vaccine #5: Rotavirus, 1 dose(s) per vial, ORAL	August	Government
	Q.5: Please state any Technical Assistance needs for developing financial sustainability strategies, mobilising funding for immunization, including for co-financing	
	Technical Assistance is not needed for this.	

***Note:** co-financing is not mandatory for IPV

Is support from GAVI, in form of new and under-used vaccines and injection supplies, reported in the national health sector budget? **Yes**

7.5. Vaccine Management (EVSM/VMA/EVM)

Please note that Effective Vaccine Store Management (EVSM) and Vaccine Management Assessment(VMA) tools have been replaced by an integrated Effective Vaccine Management (EVM) tool. The information on EVM tool can be found at http://www.who.int/immunization/programmes_systems/supply_chain/evm/en/index3.html

It is mandatory for the countries to conduct an EVM prior to an application for introduction of a new vaccine. This assessment concludes with an Improvement Plan including activities and timelines whose progress report is reported with annual report. The EVM assessment is valid for a period of three years.

When was the latest Effective Vaccine Management (EVM) or an alternative assessment (EVSM/VMA) carried out? **November 2014**

Please attach:

(a) EVM assessment **(Document No 12)**

(b) Improvement plan after EVM **(Document No 13)**

(c) Progress report on the activities implemented during the year and status of implementation of recommendations from the Improvement Plan **(Document No 14)**

Progress report on EVM/VMA/EVSM Improvement Plan' is a mandatory requirement

Are there any changes in the Improvement plan, with reasons? **No**

If yes, provide details

When is the next Effective Vaccine Management (EVM) assessment planned? **November 2017**

7.6. Monitoring GAVI Support for Preventive Campaigns in 2014

Gambia does not report on NVS Preventive campaign

7.7. Change of vaccine presentation

Gambia does not require to change any of the vaccine presentation(s) for future years.

7.8. Renewal of multi-year vaccines support for those countries whose current support is ending in 2015

If 2015 is the last year of approved multiyear support for a certain vaccine and the country wishes to extend GAVI support, the country should request for an extension of the co-financing agreement with GAVI for vaccine support starting from 2016 and for the duration of a new Comprehensive Multi-Year Plan (cMYP).

The country hereby requests an extension of GAVI support for the years 2016 to 2020 for the following vaccines:

* **DTP-HepB-Hib, 10 dose(s) per vial, LIQUID**
* **IPV, 10 dose(s) per vial, LIQUID**
* **Measles second dose, 10 dose(s) per vial, LYOPHILISED**
* **Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID**
* **Rotavirus, 3-dose schedule**

At the same time it commits itself to co-finance the procurement of the following vaccines in accordance with the minimum Gavi co-financing levels as summarised in section 7.11 Calculation of requirements.

* **DTP-HepB-Hib, 10 dose(s) per vial, LIQUID**
* **IPV, 10 dose(s) per vial, LIQUID**

* **Measles second dose, 10 dose(s) per vial, LYOPHILISED**
* **Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID**
* **Rotavirus, 3-dose schedule**

The multi-year support extension is in line with the new cMYP for the years 2016 to 2020, which is attached to this APR (Document N°**16**). The new costing tool is also attached (Document N°**17**) for the following vaccines:

* **DTP-HepB-Hib, 10 dose(s) per vial, LIQUID**
* **IPV, 10 dose(s) per vial, LIQUID**
* **Measles second dose, 10 dose(s) per vial, LYOPHILISED**
* **Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID**
* **Rotavirus, 3-dose schedule**

The country ICC has endorsed this request for extended support of the following vaccines at the ICC meeting whose minutes are attached to this APR. (Document N°**18**)

* **DTP-HepB-Hib, 10 dose(s) per vial, LIQUID**
* **IPV, 10 dose(s) per vial, LIQUID**
* **Measles second dose, 10 dose(s) per vial, LYOPHILISED**
* **Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID**
* **Rotavirus, 3-dose schedule**

7.9. Request for continued support for vaccines for 2016 vaccination programme

In order to request NVS support for 2016 vaccination do the following

Confirm here below that your request for 2016 vaccines support is as per 7.11 Calculation of requirements **Yes**

If you don’t confirm, please explain

7.10. Weighted average prices of supply and related freight cost

Table 7.10.1: Commodities Cost

Estimated prices of supply are not disclosed

Table 7.10.2: Freight Cost

Vaccine Antigen	Vaccine Type	2009	2010	2011	2012	2013	2014	2015
DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	DTP-HepB-Hib, 10 dose(s) per vial, LIQUID						3.40 %	4.30 %
IPV, 10 dose(s) per vial, LIQUID	IPV, 10 dose(s) per vial, LIQUID							7.70 %
Measles second dose, 10 dose(s) per vial, LYOPHILISED	Measles second dose, 10 dose(s) per vial, LYOPHILISED						13.80 %	13.00 %
Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID						4.40 %	4.50 %
Rotavirus, 3-dose schedule	Rotavirus, 3-dose schedule						7.10 %	7.10 %

Vaccine Antigen	Vaccine Type	2016	2017	2018	2019	2020
DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	DTP-HepB-Hib, 10 dose(s) per vial, LIQUID	3.60 %	4.40 %	4.40 %	4.40 %	4.40 %
IPV, 10 dose(s) per vial, LIQUID	IPV, 10 dose(s) per vial, LIQUID	7.50 %	8.60 %	8.60 %	9.90 %	9.90 %
Measles second dose, 10 dose(s) per vial, LYOPHILISED	Measles second dose, 10 dose(s) per vial, LYOPHILISED	12.60 %	12.30 %	12.00 %	11.80 %	11.40 %
Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID	3.00 %	4.50 %	4.60 %	3.10 %	3.10 %
Rotavirus, 3-dose schedule	Rotavirus, 3-dose schedule	7.10 %	8.30 %	11.10 %	7.20 %	7.20 %

7.11. Calculation of requirements

Table 7.11.1: Specifications for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID

ID		Source		2014	2015	2016	2017	2018
	Number of surviving infants	Parameter	#	77,820	79,921	81,991	83,877	85,806
	Number of children to be vaccinated with the first dose	Parameter	#	77,821	79,122	81,171	83,038	84,948
	Number of children to be vaccinated with the third dose	Parameter	#	77,821	79,122	81,171	83,038	84,948
	Immunisation coverage with the third dose	Parameter	%	100.00 %	99.00 %	99.00 %	99.00 %	99.00 %
	Number of doses per child	Parameter	#	3	3	3	3	3
	Estimated vaccine wastage factor	Parameter	#	1.18	1.11	1.11	1.11	1.09

	Stock in Central Store Dec 31, 2014		#	56,000				
	Stock across second level Dec 31, 2014 (if available)*		#					
	Stock across third level Dec 31, 2014 (if available)*	Parameter	#					
	Number of doses per vial	Parameter	#		10	10	10	10
	AD syringes required	Parameter	#		Yes	Yes	Yes	Yes
	Reconstitution syringes required	Parameter	#		No	No	No	No
	Safety boxes required	Parameter	#		Yes	Yes	Yes	Yes
cc	**Country co-financing per dose**	Parameter	$		0.20	0.20	0.20	0.20
ca	**AD syringe price per unit**	Parameter	$		0.0448	0.0448	0.0448	0.0448
cr	**Reconstitution syringe price per unit**	Parameter	$		0	0	0	0
cs	**Safety box price per unit**	Parameter	$		0.0054	0.0054	0.0054	0.0054
fv	**Freight cost as % of vaccines value**	Parameter	%		4.30 %	3.60 %	4.40 %	4.40 %

ID		Source		2019	2020	TOTAL
	Number of surviving infants	Parameter	#	88,380	91,031	588,826
	Number of children to be vaccinated with the first dose	Parameter	#	87,496	90,121	583,717
	Number of children to be vaccinated with the third dose	Parameter	#	87,496	90,121	583,717
	Immunisation coverage with the third dose	Parameter	%	99.00 %	99.00 %	
	Number of doses per child	Parameter	#	3	3	
	Estimated vaccine wastage factor	Parameter	#	1.09	1.09	
	Number of doses per vial	Parameter	#	10	10	
	AD syringes required	Parameter	#	Yes	Yes	
	Reconstitution syringes required	Parameter	#	No	No	
	Safety boxes required	Parameter	#	Yes	Yes	
cc	**Country co-financing per dose**	Parameter	$	0.20	0.20	
ca	**AD syringe price per unit**	Parameter	$	0.0448	0.0448	
cr	**Reconstitution syringe price per unit**	Parameter	$	0	0	
cs	**Safety box price per unit**	Parameter	$	0.0054	0.0054	
fv	**Freight cost as % of vaccines value**	Parameter	%	4.40 %	4.40 %	

* Please describe the method used for stock count in the text box below. We assume the closing stock (Dec 31, 2014) is the same as the opening stock (Jan 1, {1}). If there is a difference, please provide details in the text box below.

At the end of each month, a physical count is conducted to verify end of month stock balance and vaccine ledger updated

For pentavalent vaccines, GAVI applies a benchmark of 4.5 months of buffer + operational stocks. Countries should state their buffer + operational stock requirements when different from the benchmark up to a maximum of 6 months. For support on how to calculate the buffer and operational stock levels, please contact WHO or UNICEF. By default, a buffer + operational stock of 4.5 months is pre-selected.

Not defined

Co-financing tables for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID

Co-financing group	Low

	2014	2015	2016	2017	2018
Minimum co-financing	0.20	0.20	0.20	0.20	0.20
Recommended co-financing as per			0.20	0.20	0.20
Your co-financing	0.20	0.20	0.20	0.20	0.20

	2019	2020
Minimum co-financing	0.20	0.20
Recommended co-financing as per	0.20	0.20
Your co-financing	0.20	0.20

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#	339,100	200,000	319,100	331,300	332,600
Number of AD syringes	#	367,100	215,400	363,400	388,100	395,000
Number of re-constitution syringes	#	0	0	0	0	0
Number of safety boxes	#	4,075	2,375	3,950	4,200	4,225
Total value to be co-financed by GAVI	$	716,000	416,000	609,000	527,500	530,000

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2019	2020
Number of vaccine doses	#	342,600	353,000
Number of AD syringes	#	406,800	419,000
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	4,350	4,475
Total value to be co-financed by GAVI	$	546,000	561,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#	36,800	22,000	38,500	49,300	49,500
Number of AD syringes	#	0	0	0	0	0
Number of re-constitution syringes	#	0	0	0	0	0
Number of safety boxes	#	0	0	0	0	0
Total value to be co-financed by the Country *[1]*	$	75,500	44,500	73,500	78,500	79,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2019	2020
Number of vaccine doses	#	51,000	52,600
Number of AD syringes	#	0	0
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	0	0
Total value to be co-financed by the Country *[1]*	$	81,500	84,000

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (part 1)

		Formula	2014	2015		
				Total	Government	GAVI
A	Country co-finance	*V*				
B	Number of children to be vaccinated with the second dose	*Table 4*	77,821	79,122		
B1	Number of children to be vaccinated with the third dose	*Table 4*	77,821	79,122		
C	Number of doses per child	*Vaccine parameter (schedule)*	3	3		
D	Number of doses needed	*B + B1 + Target for the 2nd dose ((B -0.41 x (B - B1))*	233,463	237,366		
E	Estimated vaccine wastage factor	*Table 4*	1.18	1.11		
F	Number of doses needed including wastage	*D x E*		263,477		
G	Vaccines buffer stock	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.375* ***Buffer on doses wasted*** *=* • *if(wastage factor of previous year current estimation < wastage factor of previous year original approved): ((F - D) - ((F - D) of previous year original approved - (F - D) of previous year current estimation)) x 0.375* • *else: (F - D - ((F - D) of previous year original approved)) x 0.375 >= 0*				
H	Stock to be deducted	*H1 - (F (2015) current estimation x 0.375)*				
H1	Calculated opening stock	*H2 (2015) + H3 (2015) - F (2015)*				
H2	Reported stock on January 1st	*Table 7.11.1*	44,590	56,000		
H3	Shipment plan	*Approved volume*		222,000		
I	Total vaccine doses needed	*Round up((F + G - H) / vaccine package size) x vaccine package size*		222,000		
J	Number of doses per vial	*Vaccine Parameter*				
K	Number of AD syringes (+ 10% wastage) needed	*(D + G – H) x 1.10*				
L	Reconstitution syringes (+ 10% wastage) needed	*(I / J) x 1.10*				
M	Total of safety boxes (+ 10% of extra need) needed	*(I / 100) x 1.10*				
N	Cost of vaccines needed	*I x vaccine price per dose (g)*				
O	Cost of AD syringes needed	*K x AD syringe price per unit (ca)*				
P	Cost of reconstitution syringes needed	*L x reconstitution price per unit (cr)*				
Q	Cost of safety boxes needed	*M x safety box price per unit (cs)*				
R	Freight cost for vaccines needed	*N x freight cost as of % of vaccines value (fv)*				
S	Freight cost for devices needed	*(O+P+Q) x freight cost as % of devices value (fd)*				
T	Total fund needed	*(N+O+P+Q+R+S)*				
U	Total country co-financing	*I x country co-financing per dose (cc)*				
V	Country co-financing % of GAVI supported proportion	*U / (N + R)*				

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (part 2)

		Formula	2016

			Total	Government	GAVI
A	**Country co-finance**	*V*	10.74 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	81,171	8,721	72,450
B1	**Number of children to be vaccinated with the third dose**	*Table 4*	81,171	8,721	72,450
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B + B1 + Target for the 2nd dose ((B -0.41 x (B - B1))*	243,513	26,161	217,352
E	**Estimated vaccine wastage factor**	*Table 4*	1.11		
F	**Number of doses needed including wastage**	*D X E*	270,300	29,039	241,261
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.375* ***Buffer on doses wasted*** *=* • *if(wastage factor of previous year current estimation < wastage factor of previous year original approved): ((F - D) - ((F - D) of previous year original approved - (F - D) of previous year current estimation)) x 0.375* • *else: (F - D - ((F - D) of previous year original approved)) x 0.375 >= 0*	2,559	275	2,284
H	**Stock to be deducted**	*H1 - (F (2015) current estimation x 0.375)*	- 84,279	- 9,054	- 75,225
H1	**Calculated opening stock**	*H2 (2015) + H3 (2015) - F (2015)*	14,524	1,561	12,963
H2	**Reported stock on January 1st**	*Table 7.11.1*			
H3	**Shipment plan**	*Approved volume*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	357,500	38,406	319,094
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	363,387	0	363,387
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	3,933	0	3,933
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	642,428	69,016	573,412
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	16,280	0	16,280
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	22	0	22
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	23,128	2,485	20,643
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	681,858	73,252	608,606
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	71,500		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	10.74 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (part 3)

		Formula	2017		
			Total	Government	GAVI
A	**Country co-finance**	*V*	12.94 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	83,038	10,742	72,296
B1	**Number of children to be vaccinated**	*Table 4*	83,038	10,742	72,296

	with the third dose				
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B + B1 + Target for the 2nd dose ((B -0.41 x (B - B1))*	249,114	32,224	216,890
E	**Estimated vaccine wastage factor**	*Table 4*	1.11		
F	**Number of doses needed including wastage**	*D X E*	276,517	35,769	240,748
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.375* ***Buffer on doses wasted*** *=* • *if(wastage factor of previous year current estimation < wastage factor of previous year original approved): ((F - D) - ((F - D) of previous year original approved - (F - D) of previous year current estimation)) x 0.375* • *else: (F - D - ((F - D) of previous year original approved)) x 0.375 >= 0*	103,694	13,414	90,280
H	**Stock to be deducted**	*H1 - (F (2015) current estimation x 0.375)*			
H1	**Calculated opening stock**	*H2 (2015) + H3 (2015) - F (2015)*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
H3	**Shipment plan**	*Approved volume*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	380,500	49,219	331,281
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	388,089	0	388,089
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	4,186	0	4,186
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	563,521	72,893	490,628
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	17,387	0	17,387
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	23	0	23
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	24,795	3,208	21,587
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	605,726	78,353	527,373
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	76,100		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	12.94 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (part 4)

		Formula	**2018**		
			Total	**Government**	**GAVI**
A	**Country co-finance**	*V*	12.94 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	84,948	10,989	73,959
B1	**Number of children to be vaccinated with the third dose**	*Table 4*	84,948	10,989	73,959
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B + B1 + Target for the 2nd dose ((B -0.41 x (B - B1))*	254,844	32,965	221,879
E	**Estimated vaccine wastage factor**	*Table 4*	1.09		

F	**Number of doses needed including wastage**	*D X E*	277,780	35,932	241,848
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.375* ***Buffer on doses wasted*** *=* • *if(wastage factor of previous year current estimation < wastage factor of previous year original approved): ((F - D) - ((F - D) of previous year original approved - (F - D) of previous year current estimation)) x 0.375* • *else: (F - D - ((F - D) of previous year original approved)) x 0.375 >= 0*	104,168	13,475	90,693
H	**Stock to be deducted**	*H1 - (F (2015) current estimation x 0.375)*			
H1	**Calculated opening stock**	*H2 (2015) + H3 (2015) - F (2015)*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
H3	**Shipment plan**	*Approved volume*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	382,000	49,413	332,587
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	394,914	0	394,914
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	4,202	0	4,202
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	565,742	73,181	492,561
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	17,693	0	17,693
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	23	0	23
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	24,893	3,220	21,673
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	608,351	78,692	529,659
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	76,400		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	12.94 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (part 5)

		Formula	**2019**		
			Total	**Government**	**GAVI**
A	**Country co-finance**	*V*	12.94 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	87,496	11,318	76,178
B1	**Number of children to be vaccinated with the third dose**	*Table 4*	87,496	11,318	76,178
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B + B1 + Target for the 2nd dose ((B -0.41 x (B - B1))*	262,488	33,954	228,534
E	**Estimated vaccine wastage factor**	*Table 4*	1.09		
F	**Number of doses needed including wastage**	*D X E*	286,112	37,010	249,102
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.375* ***Buffer on doses wasted*** *=* • *if(wastage factor of previous year current*	107,292	13,879	93,413

		estimation < wastage factor of previous year original approved): ((F - D) - ((F - D) of previous year original approved - (F - D) of previous year current estimation)) x 0.375 • *else: (F - D - ((F - D) of previous year original approved)) x 0.375 >= 0*			
H	**Stock to be deducted**	*H1 - (F (2015) current estimation x 0.375)*			
H1	**Calculated opening stock**	*H2 (2015) + H3 (2015) - F (2015)*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
H3	**Shipment plan**	*Approved volume*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	393,500	50,901	342,599
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	406,759	0	406,759
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	4,329	0	4,329
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	582,774	75,384	507,390
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	18,223	0	18,223
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	24	0	24
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	25,643	3,317	22,326
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	626,664	81,061	545,603
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	78,700		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	12.94 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for DTP-HepB-Hib, 10 dose(s) per vial, LIQUID (part 6)

		Formula	**2020**		
			Total	**Government**	**GAVI**
A	**Country co-finance**	*V*	12.97 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	90,121	11,689	78,432
B1	**Number of children to be vaccinated with the third dose**	*Table 4*	90,121	11,689	78,432
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B + B1 + Target for the 2nd dose ((B -0.41 x (B - B1))*	270,363	35,067	235,296
E	**Estimated vaccine wastage factor**	*Table 4*	1.09		
F	**Number of doses needed including wastage**	*D X E*	294,696	38,223	256,473
G	**Vaccines buffer stock**	***Buffer on doses needed** + **buffer on doses wasted*** ***Buffer on doses needed** = (D - D of previous year original approved) x 0.375* ***Buffer on doses wasted** =* • *if(wastage factor of previous year current estimation < wastage factor of previous year original approved): ((F - D) - ((F - D) of previous year original approved - (F - D) of previous year current estimation)) x 0.375* • *else: (F - D - ((F - D) of previous year original approved)) x 0.375 >= 0*	110,511	14,334	96,177

H	**Stock to be deducted**	*H1 - (F (2015) current estimation x 0.375)*			
H1	**Calculated opening stock**	*H2 (2015) + H3 (2015) - F (2015)*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
H3	**Shipment plan**	*Approved volume*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	405,500	52,595	352,905
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	418,962	0	418,962
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	4,461	0	4,461
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	598,924	77,682	521,242
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	18,770	0	18,770
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	25	0	25
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	26,353	3,419	22,934
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	644,072	83,538	560,534
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	81,100		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	12.97 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.1: Specifications for Measles second dose, 10 dose(s) per vial, LYOPHILISED

ID		Source		2014	2015	2016	2017	TOTAL
	Number of surviving infants	Parameter	#	77,820	79,921	81,991	83,877	323,609
	Number of children to be vaccinated with the first dose	Parameter	#	0	75,926	77,072	79,683	232,681
	Number of children to be vaccinated with the second dose	Parameter	#	73,152	75,926	77,072	79,683	305,833
	Immunisation coverage with the second dose	Parameter	%	94.00 %	95.00 %	94.00 %	95.00 %	
	Number of doses per child	Parameter	#	1	1	1	1	
	Estimated vaccine wastage factor	Parameter	#	1.15	1.14	1.14	1.14	
	Stock in Central Store Dec 31, 2014		#	60,300				
	Stock across second level Dec 31, 2014 (if available)*		#					
	Stock across third level Dec 31, 2014 (if available)*	Parameter	#					
	Number of doses per vial	Parameter	#		10	10	10	
	AD syringes required	Parameter	#		Yes	Yes	Yes	
	Reconstitution syringes required	Parameter	#		Yes	Yes	Yes	
	Safety boxes required	Parameter	#		Yes	Yes	Yes	
cc	**Country co-financing per dose**	Parameter	$		0.00	0.00	0.00	
ca	**AD syringe price per unit**	Parameter	$		0.0448	0.0448	0.0448	
cr	**Reconstitution syringe price per unit**	Parameter	$		0	0	0	
cs	**Safety box price per unit**	Parameter	$		0.0054	0.0054	0.0054	
fv	**Freight cost as % of vaccines value**	Parameter	%		13.00 %	12.60 %	12.30 %	
fd	**Freight cost as % of devices value**	Parameter	%					

* Please describe the method used for stock count in the text box below. We assume the closing stock (Dec 31, 2014) is the same as the opening stock (Jan 1, {1}). If there is a difference, please provide details in the text box below.

At the end of each month, a physical count is conducted to obtain stock balance and update ledgers

Co-financing tables for Measles second dose, 10 dose(s) per vial, LYOPHILISED

Co-financing group	Low

	2014	2015	2016	2017
Minimum co-financing				
Recommended co-financing as per				
Your co-financing				

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2014	2015	2016	2017
Number of vaccine doses	#	118,200	87,300	49,600	91,600
Number of AD syringes	#	80,500	84,300	42,700	88,500

Number of re-constitution syringes	#	13,000	9,600	5,500	10,100
Number of safety boxes	#	1,050	1,050	550	1,025
Total value to be co-financed by GAVI	$	43,500	31,000	17,500	33,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015	2016	2017
Number of vaccine doses	#	0	0	0	0
Number of AD syringes	#	0	0	0	0
Number of re-constitution syringes	#	0	0	0	0
Number of safety boxes	#	0	0	0	0
Total value to be co-financed by the Country ***[1]***	$	0	0	0	0

Table 7.11.4: Calculation of requirements for Measles second dose, 10 dose(s) per vial, LYOPHILISED (part 1)

		Formula	2014	2015		
				Total	Government	GAVI
A	**Country co-finance**	*V*				
B	**Number of children to be vaccinated with the second dose**	*Table 4*	73,152	75,926		
C	**Number of doses per child**	*Vaccine parameter (schedule)*	1	1		
D	**Number of doses needed**	*B x C*	0	75,926		
E	**Estimated vaccine wastage factor**	*Table 4*	1.15	1.14		
F	**Number of doses needed including wastage**	*D x E*		86,556		
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*				
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*				
H2	**Reported stock on January 1st**	*Table 7.11.1*	0	60,300		
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*		87,300		
J	**Number of doses per vial**	*Vaccine Parameter*				
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*				
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*				
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*				
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*				
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*				
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*				
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*				
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*				
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*				
T	**Total fund needed**	*(N+O+P+Q+R+S)*				
U	**Total country co-financing**	*I x country co-financing per dose (cc)*				
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*				

Table 7.11.4: Calculation of requirements for Measles second dose, 10 dose(s) per vial, LYOPHILISED (part 2)

		Formula	2016		
			Total	Government	GAVI
A	Country co-finance	*V*	0.00 %		
B	Number of children to be vaccinated with the second dose	*Table 4*	77,072	0	77,072
C	Number of doses per child	*Vaccine parameter (schedule)*	1		
D	Number of doses needed	*B x C*	77,072	0	77,072
E	Estimated vaccine wastage factor	*Table 4*	1.14		
F	Number of doses needed including wastage	*D x E*	87,863	0	87,863
G	Vaccines buffer stock	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	327	0	327
H	Stock to be deducted	*H2 of previous year - 0.25 x F of previous year*	38,661	0	38,661
H2	Reported stock on January 1st	*Table 7.11.1*			
I	Total vaccine doses needed	*Round up((F + G - H) / vaccine package size) x vaccine package size*	49,600	0	49,600
J	Number of doses per vial	*Vaccine Parameter*	10		
K	Number of AD syringes (+ 10% wastage) needed	*(D + G – H) x 1.10*	42,612	0	42,612
L	Reconstitution syringes (+ 10% wastage) needed	*(I / J) x 1.10*	5,456	0	5,456
M	Total of safety boxes (+ 10% of extra need) needed	*(I / 100) x 1.10*	546	0	546
N	Cost of vaccines needed	*I x vaccine price per dose (g)*	13,343	0	13,343
O	Cost of AD syringes needed	*K x AD syringe price per unit (ca)*	1,910	0	1,910
P	Cost of reconstitution syringes needed	*L x reconstitution price per unit (cr)*	191	0	191
Q	Cost of safety boxes needed	*M x safety box price per unit (cs)*	3	0	3
R	Freight cost for vaccines needed	*N x freight cost as of % of vaccines value (fv)*	1,682	0	1,682
S	Freight cost for devices needed	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	Total fund needed	*(N+O+P+Q+R+S)*	17,129	0	17,129
U	Total country co-financing	*I x country co-financing per dose (cc)*	0		
V	Country co-financing % of GAVI supported proportion	*U / (N + R)*	0.00 %		

Table 7.11.4: Calculation of requirements for Measles second dose, 10 dose(s) per vial, LYOPHILISED (part 3)

		Formula	2017		
			Total	Government	GAVI
A	Country co-finance	*V*	0.00 %		
B	Number of children to be vaccinated with the second dose	*Table 4*	79,683	0	79,683
C	Number of doses per child	*Vaccine parameter (schedule)*	1		
D	Number of doses needed	*B x C*	79,683	0	79,683
E	Estimated vaccine wastage factor	*Table 4*	1.14		
F	Number of doses needed including wastage	*D x E*	90,839	0	90,839
G	Vaccines buffer stock	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	745	0	745
H	Stock to be deducted	*H2 of previous year - 0.25 x F of previous year*			
H2	Reported stock on January 1st	*Table 7.11.1*			
I	Total vaccine doses needed	*Round up((F + G - H) / vaccine package size) x vaccine package size*	91,600	0	91,600
J	Number of doses per vial	*Vaccine Parameter*	10		
K	Number of AD syringes (+ 10% wastage) needed	*(D + G – H) x 1.10*	88,471	0	88,471
L	Reconstitution syringes (+ 10% wastage) needed	*(I / J) x 1.10*	10,076	0	10,076
M	Total of safety boxes (+ 10% of extra need) needed	*(I / 100) x 1.10*	1,008	0	1,008
N	Cost of vaccines needed	*I x vaccine price per dose (g)*	25,282	0	25,282
O	Cost of AD syringes needed	*K x AD syringe price per unit (ca)*	3,964	0	3,964
P	Cost of reconstitution syringes needed	*L x reconstitution price per unit (cr)*	353	0	353
Q	Cost of safety boxes needed	*M x safety box price per unit (cs)*	6	0	6
R	Freight cost for vaccines needed	*N x freight cost as of % of vaccines value (fv)*	3,110	0	3,110
S	Freight cost for devices needed	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	Total fund needed	*(N+O+P+Q+R+S)*	32,715	0	32,715
U	Total country co-financing	*I x country co-financing per dose (cc)*	0		
V	Country co-financing % of GAVI supported proportion	*U / (N + R)*	0.00 %		

Table 7.11.1: Specifications for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID

ID		Source		2014	2015	2016	2017	2018
	Number of surviving infants	Parameter	#	77,820	79,921	81,991	83,877	85,806
	Number of children to be vaccinated with the first dose	Parameter	#	77,042	79,122	81,171	83,038	84,948
	Number of children to be vaccinated with the third dose	Parameter	#	77,042	79,122	81,171	83,038	84,948
	Immunisation coverage with the third dose	Parameter	%	99.00 %	99.00 %	99.00 %	99.00 %	99.00 %
	Number of doses per child	Parameter	#	3	3	3	3	3
	Estimated vaccine wastage factor	Parameter	#	1.05	1.05	1.05	1.04	1.04
	Stock in Central Store Dec 31, 2014		#	94,950				
	Stock across second level Dec 31, 2014 (if available)*		#					
	Stock across third level Dec 31, 2014 (if available)*	Parameter	#					
	Number of doses per vial	Parameter	#		1	1	1	1
	AD syringes required	Parameter	#		Yes	Yes	Yes	Yes
	Reconstitution syringes required	Parameter	#		No	No	No	No
	Safety boxes required	Parameter	#		Yes	Yes	Yes	Yes
cc	**Country co-financing per dose**	Parameter	$		0.20	0.20	0.20	0.20
ca	**AD syringe price per unit**	Parameter	$		0.0448	0.0448	0.0448	0.0448
cr	**Reconstitution syringe price per unit**	Parameter	$		0	0	0	0
cs	**Safety box price per unit**	Parameter	$		0.0054	0.0054	0.0054	0.0054
fv	**Freight cost as % of vaccines value**	Parameter	%		4.50 %	3.00 %	4.50 %	4.60 %

ID		Source		2019	2020	TOTAL
	Number of surviving infants	Parameter	#	88,380	91,031	588,826
	Number of children to be vaccinated with the first dose	Parameter	#	87,496	90,121	582,938
	Number of children to be vaccinated with the third dose	Parameter	#	87,496	90,121	582,938
	Immunisation coverage with the third dose	Parameter	%	99.00 %	99.00 %	
	Number of doses per child	Parameter	#	3	3	
	Estimated vaccine wastage factor	Parameter	#	1.04	1.04	
	Number of doses per vial	Parameter	#	1	1	
	AD syringes required	Parameter	#	Yes	Yes	
	Reconstitution syringes required	Parameter	#	No	No	
	Safety boxes required	Parameter	#	Yes	Yes	
cc	**Country co-financing per dose**	Parameter	$	0.20	0.20	
ca	**AD syringe price per unit**	Parameter	$	0.0448	0.0448	
cr	**Reconstitution syringe price per unit**	Parameter	$	0	0	
cs	**Safety box price per unit**	Parameter	$	0.0054	0.0054	
fv	**Freight cost as % of vaccines value**	Parameter	%	3.10 %	3.10 %	

* Please describe the method used for stock count in the text box below. We assume the closing stock (Dec 31, 2014) is the same as the opening stock (Jan 1, {1}). If there is a difference, please provide details in the text box below.

At the end of each month, a physical count is conducted to verify the stock balance and ledgers updated.

Co-financing tables for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID

Co-financing group	Low

	2014	2015	2016	2017	2018
Minimum co-financing	0.20	0.20	0.20	0.20	0.20
Recommended co-financing as per			0.20	0.20	0.20
Your co-financing	0.20	0.20	0.20	0.20	0.20

	2019	2020
Minimum co-financing	0.20	0.20
Recommended co-financing as per	0.20	0.20
Your co-financing	0.20	0.20

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#	231,300	217,800	212,100	303,700	310,200
Number of AD syringes	#	256,700	241,200	233,800	342,000	350,500
Number of re-constitution syringes	#	0	0	0	0	0
Number of safety boxes	#	2,850	2,675	2,475	3,550	3,625
Total value to be co-financed by GAVI	$	847,000	796,500	748,000	1,069,500	1,076,000

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2019	2020
Number of vaccine doses	#	319,900	328,300
Number of AD syringes	#	361,100	371,900
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	3,750	3,850
Total value to be co-financed by GAVI	$	1,084,000	1,111,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#	13,700	14,400	13,000	18,600	19,300
Number of AD syringes	#	0	0	0	0	0
Number of re-constitution syringes	#	0	0	0	0	0
Number of safety boxes	#	0	0	0	0	0
Total value to be co-financed by the Country *[1]*	$	49,000	46,500	46,000	65,500	67,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2019	2020
Number of vaccine doses	#	20,400	21,000
Number of AD syringes	#	0	0
Number of re-constitution syringes	#	0	0

Number of safety boxes	#	0	0
Total value to be co-financed by the Country ***[1]***	$	69,500	71,000

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID (part 1)

		Formula	2014	2015		
				Total	Government	GAVI
A	**Country co-finance**	*V*				
B	**Number of children to be vaccinated with the second dose**	*Table 4*	77,042	79,122		
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3	3		
D	**Number of doses needed**	*B x C*	231,126	237,366		
E	**Estimated vaccine wastage factor**	*Table 4*	1.05	1.05		
F	**Number of doses needed including wastage**	*D x E*		249,235		
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*				
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*				
H2	**Reported stock on January 1st**	*Table 7.11.1*	30,500	94,950		
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*		232,200		
J	**Number of doses per vial**	*Vaccine Parameter*				
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*				
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*				
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*				
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*				
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*				
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*				
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*				
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*				
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*				
T	**Total fund needed**	*(N+O+P+Q+R+S)*				
U	**Total country co-financing**	*I x country co-financing per dose (cc)*				
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*				

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID (part 2)

		Formula	2016		
			Total	Government	GAVI
A	**Country co-finance**	*V*	5.75 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	81,171	4,666	76,505
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	243,513	13,998	229,515
E	**Estimated vaccine wastage factor**	*Table 4*	1.05		
F	**Number of doses needed including wastage**	*D x E*	255,689	14,698	240,991
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	1,614	93	1,521
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*	32,642	1,877	30,765
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	225,000	12,934	212,066
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	233,734	0	233,734
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	2,475	0	2,475
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	760,050	43,690	716,360
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	10,472	0	10,472
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	14	0	14
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	22,802	1,311	21,491
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	793,338	45,603	747,735
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	45,000		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	5.75 %		

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID (part 3)

		Formula	2017		
			Total	Government	GAVI
A	**Country co-finance**	*V*	5.76 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	83,038	4,782	78,256
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	249,114	14,344	234,770
E	**Estimated vaccine wastage factor**	*Table 4*	1.04		
F	**Number of doses needed including wastage**	*D x E*	259,079	14,918	244,161
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	61,726	3,555	58,171
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	322,200	18,552	303,648
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	341,924	0	341,924
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	3,545	0	3,545
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	1,070,993	61,666	1,009,327
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	15,319	0	15,319
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	20	0	20
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	48,195	2,775	45,420
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	1,134,527	65,324	1,069,203
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	64,440		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	5.76 %		

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID (part 5)

		Formula	2019		
			Total	Government	GAVI
A	**Country co-finance**	*V*	5.99 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	87,496	5,239	82,257
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	262,488	15,716	246,772
E	**Estimated vaccine wastage factor**	*Table 4*	1.04		
F	**Number of doses needed including wastage**	*D x E*	272,988	16,345	256,643
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	65,699	3,934	61,765
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	340,200	20,369	319,831
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	361,006	0	361,006
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	3,743	0	3,743
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	1,102,248	65,995	1,036,253
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	16,174	0	16,174
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	21	0	21
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	34,170	2,046	32,124
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	1,152,613	69,010	1,083,603
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	68,040		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	5.99 %		

Table 7.11.4: Calculation of requirements for Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID (part 6)

		Formula	2020		
			Total	Government	GAVI
A	**Country co-finance**	*V*	6.00 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	90,121	5,405	84,716
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	270,363	16,213	254,150
E	**Estimated vaccine wastage factor**	*Table 4*	1.04		
F	**Number of doses needed including wastage**	*D x E*	281,178	16,861	264,317
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	67,670	4,058	63,612
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	349,200	20,940	328,260
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	371,837	0	371,837
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	3,842	0	3,842
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	1,129,662	67,741	1,061,921
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	16,659	0	16,659
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	21	0	21
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	35,020	2,100	32,920
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	1,181,362	70,841	1,110,521
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	69,840		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	6.00 %		

Table 7.11.1: Specifications for Rotavirus, 3-dose schedule

ID		Source		2014	2015	2016	2017	2018
	Number of surviving infants	Parameter	#	77,820	79,921	81,991	83,877	85,806
	Number of children to be vaccinated with the first dose	Parameter	#	72,373	79,122	81,171	83,038	84,948
	Number of children to be vaccinated with the third dose	Parameter	#	72,373	79,122	81,171	83,038	84,948
	Immunisation coverage with the third dose	Parameter	%	93.00 %	99.00 %	99.00 %	99.00 %	99.00 %
	Number of doses per child	Parameter	#	3	3	3	3	3
	Estimated vaccine wastage factor	Parameter	#	1.05	1.05	1.05	1.05	1.04
	Stock in Central Store Dec 31, 2014		#	109,400				
	Stock across second level Dec 31, 2014 (if available)*		#					
	Stock across third level Dec 31, 2014 (if available)*	Parameter	#					
	Number of doses per vial	Parameter	#		1	1	1	1
	AD syringes required	Parameter	#		No	No	No	No
	Reconstitution syringes required	Parameter	#		No	No	No	No
	Safety boxes required	Parameter	#		No	No	No	No
cc	**Country co-financing per dose**	Parameter	$		0.13	0.13	0.13	0.13
ca	**AD syringe price per unit**	Parameter	$		0.0448	0.0448	0.0448	0.0448
cr	**Reconstitution syringe price per unit**	Parameter	$		0	0	0	0
cs	**Safety box price per unit**	Parameter	$		0.0054	0.0054	0.0054	0.0054
fv	**Freight cost as % of vaccines value**	Parameter	%		7.10 %	7.10 %	8.30 %	11.10 %

ID		Source		2019	2020	TOTAL
	Number of surviving infants	Parameter	#	88,380	91,031	588,826
	Number of children to be vaccinated with the first dose	Parameter	#	87,496	90,121	578,269
	Number of children to be vaccinated with the third dose	Parameter	#	87,496	90,121	578,269
	Immunisation coverage with the third dose	Parameter	%	99.00 %	99.00 %	
	Number of doses per child	Parameter	#	3	3	
	Estimated vaccine wastage factor	Parameter	#	1.04	1.04	
	Number of doses per vial	Parameter	#	1	1	
	AD syringes required	Parameter	#	No	No	
	Reconstitution syringes required	Parameter	#	No	No	
	Safety boxes required	Parameter	#	No	No	
cc	**Country co-financing per dose**	Parameter	$	0.13	0.13	
ca	**AD syringe price per unit**	Parameter	$	0.0448	0.0448	
cr	**Reconstitution syringe price per unit**	Parameter	$	0	0	
cs	**Safety box price per unit**	Parameter	$	0.0054	0.0054	
fv	**Freight cost as % of vaccines value**	Parameter	%	7.20 %	7.20 %	

* Please describe the method used for stock count in the text box below. We assume the closing stock (Dec 31, 2014) is the same as the opening stock (Jan 1, {1}). If there is a difference, please provide details in the text box below.

A physical count is conducted at the end of every month to obtain the stock balance and update the ledgers.

Co-financing tables for Rotavirus, 3-dose schedule

Co-financing group	Low

	2014	2015	2016	2017	2018
Minimum co-financing	0.13	0.13	0.13	0.13	0.13
Recommended co-financing as per			0.13	0.13	0.13
Your co-financing	0.13	0.13	0.13	0.13	0.13

	2019	2020
Minimum co-financing	0.13	0.13
Recommended co-financing as per	0.13	0.13
Your co-financing	0.13	0.13

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#	221,900	245,700	203,300	252,800	311,500
Number of AD syringes	#	0	0	0	0	0
Number of re-constitution syringes	#	0	0	0	0	0
Number of safety boxes	#	0	0	0	0	0
Total value to be co-financed by GAVI	$	816,500	922,500	762,500	821,500	782,500

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2019	2020
Number of vaccine doses	#	319,200	328,800
Number of AD syringes	#	0	0
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	0	0
Total value to be co-financed by GAVI	$	714,000	731,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#	8,600	9,000	7,400	10,600	17,100
Number of AD syringes	#	0	0	0	0	0
Number of re-constitution syringes	#	0	0	0	0	0
Number of safety boxes	#	0	0	0	0	0
Total value to be co-financed by the Country *[1]*	$	30,500	33,500	27,500	34,500	43,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2019	2020
Number of vaccine doses	#	19,700	20,500
Number of AD syringes	#	0	0
Number of re-constitution syringes	#	0	0

Number of safety boxes	#	0	0
Total value to be co-financed by the Country ***[1]***	$	44,500	45,500

Table 7.11.4: Calculation of requirements for Rotavirus, 3-dose schedule (part 1)

		Formula	2014	2015		
				Total	Government	GAVI
A	**Country co-finance**	*V*				
B	**Number of children to be vaccinated with the second dose**	*Table 4*	72,373	79,122		
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3	3		
D	**Number of doses needed**	*B x C*	217,119	237,366		
E	**Estimated vaccine wastage factor**	*Table 4*	1.05	1.05		
F	**Number of doses needed including wastage**	*D x E*		249,235		
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*				
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*				
H2	**Reported stock on January 1st**	*Table 7.11.1*	0	109,400		
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*		254,700		
J	**Number of doses per vial**	*Vaccine Parameter*				
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*				
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*				
M	**Total of safety boxes (+ 10% of extra need) needed**	*(K + L) / 100 x 1.10*				
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*				
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*				
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*				
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*				
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*				
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*				
T	**Total fund needed**	*(N+O+P+Q+R+S)*				
U	**Total country co-financing**	*I x country co-financing per dose (cc)*				
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*				

Table 7.11.4: Calculation of requirements for Rotavirus, 3-dose schedule (part 2)

		Formula	2016		
			Total	Government	GAVI
A	**Country co-finance**	*V*	3.47 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	81,171	2,816	78,355
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	243,513	8,446	235,067
E	**Estimated vaccine wastage factor**	*Table 4*	1.05		
F	**Number of doses needed including wastage**	*D x E*	255,689	8,868	246,821
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	1,614	56	1,558
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*	47,092	1,634	45,458
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	210,600	7,304	203,296
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	0	0	0
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(K + L) / 100 x 1.10*	0	0	0
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	737,100	25,563	711,537
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	0	0	0
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	0	0	0
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	52,335	1,816	50,519
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	789,435	27,379	762,056
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	27,378		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	3.47 %		

Table 7.11.4: Calculation of requirements for Rotavirus, 3-dose schedule (part 3)

		Formula	2017		
			Total	Government	GAVI
A	**Country co-finance**	*V*	4.00 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	83,038	3,323	79,715
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	249,114	9,968	239,146
E	**Estimated vaccine wastage factor**	*Table 4*	1.05		
F	**Number of doses needed including wastage**	*D x E*	261,570	10,467	251,103
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	1,471	59	1,412
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	263,250	10,534	252,716
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	0	0	0
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(K + L) / 100 x 1.10*	0	0	0
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	789,750	31,601	758,149
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	0	0	0
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	0	0	0
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	65,550	2,623	62,927
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	855,300	34,223	821,077
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	34,223		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	4.00 %		

Table 7.11.4: Calculation of requirements for Rotavirus, 3-dose schedule (part 5)

		Formula	2019		
			Total	Government	GAVI
A	**Country co-finance**	*V*	5.81 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	87,496	5,087	82,409
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	262,488	15,260	247,228
E	**Estimated vaccine wastage factor**	*Table 4*	1.04		
F	**Number of doses needed including wastage**	*D x E*	272,988	15,871	257,117
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	65,699	3,820	61,879
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	338,850	19,700	319,150
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	0	0	0
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(K + L) / 100 x 1.10*	0	0	0
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	706,842	41,093	665,749
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	0	0	0
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	0	0	0
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	50,893	2,959	47,934
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	757,735	44,051	713,684
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	44,051		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	5.81 %		

Table 7.11.4: Calculation of requirements for Rotavirus, 3-dose schedule (part 6)

		Formula	2020		
			Total	Government	GAVI
A	**Country co-finance**	*V*	5.85 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	90,121	5,272	84,849
C	**Number of doses per child**	*Vaccine parameter (schedule)*	3		
D	**Number of doses needed**	*B x C*	270,363	15,816	254,547
E	**Estimated vaccine wastage factor**	*Table 4*	1.04		
F	**Number of doses needed including wastage**	*D x E*	281,178	16,449	264,729
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	67,670	3,959	63,711
H	**Stock to be deducted**	*H2 of previous year - 0.25 x F of previous year*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	349,200	20,428	328,772
J	**Number of doses per vial**	*Vaccine Parameter*	1		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	0	0	0
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(K + L) / 100 x 1.10*	0	0	0
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	723,892	42,347	681,545
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	0	0	0
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	0	0	0
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	52,121	3,050	49,071
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	776,013	45,396	730,617
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	45,396		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	5.85 %		

Table 7.11.1: Specifications for IPV, 10 dose(s) per vial, LIQUID

ID		Source		2014	2015	2016	2017	2018
	Number of surviving infants	Parameter	#	77,820	79,921	81,991	83,877	85,806
	Number of children to be vaccinated	Parameter	#	0	77,017	0.00 %	83,038	0.00 %
	Number of doses per child	Parameter	#	1	1	1	1	1
	Estimated vaccine wastage factor	Parameter	#	1.00	2.00	2.00	2.00	2.00
	Stock in Central Store Dec 31, 2014		#	0				
	Stock across second level Dec 31, 2014 (if available)*		#					
	Stock across third level Dec 31, 2014 (if available)*	Parameter	#					
	Number of doses per vial	Parameter	#		10	10	10	10
	AD syringes required	Parameter	#		Yes	Yes	Yes	Yes
	Reconstitution syringes required	Parameter	#		No	No	No	No
	Safety boxes required	Parameter	#		Yes	Yes	Yes	Yes
cc	**Country co-financing per dose**	Parameter	$		0.00	0.00	0.00	0.00
ca	**AD syringe price per unit**	Parameter	$		0.0448	0.0448	0.0448	0.0448
cr	**Reconstitution syringe price per unit**	Parameter	$		0	0	0	0
cs	**Safety box price per unit**	Parameter	$		0.0054	0.0054	0.0054	0.0054
fv	**Freight cost as % of vaccines value**	Parameter	%		7.70 %	7.50 %	8.60 %	8.60 %

ID		Source		2019	2020	TOTAL
	Number of surviving infants	Parameter	#	88,380	91,031	588,826
	Number of children to be vaccinated	Parameter	#	87,496	90,121	503,791
	Number of doses per child	Parameter	#	1	1	
	Estimated vaccine wastage factor	Parameter	#	1.67	1.67	
	Number of doses per vial	Parameter	#	10	10	
	AD syringes required	Parameter	#	Yes	Yes	
	Reconstitution syringes required	Parameter	#	No	No	
	Safety boxes required	Parameter	#	Yes	Yes	
cc	**Country co-financing per dose**	Parameter	$	0.00	0.00	
ca	**AD syringe price per unit**	Parameter	$	0.0448	0.0448	
cr	**Reconstitution syringe price per unit**	Parameter	$	0	0	
cs	**Safety box price per unit**	Parameter	$	0.0054	0.0054	
fv	**Freight cost as % of vaccines value**	Parameter	%	9.90 %	9.90 %	

* Please describe the method used for stock count in the text box below. We assume the closing stock (Dec 31, 2014) is the same as the opening stock (Jan 1, {1}). If there is a difference, please provide details in the text box below.

Nil

Co-financing tables for IPV, 10 dose(s) per vial, LIQUID

Co-financing group	Low

	2014	2015	2016	2017	2018
Minimum co-financing			0.00	0.00	0.00

Recommended co-financing as per			0.00	0.00	0.00
Your co-financing		0.00	0.00	0.00	0.00

	2019	2020
Minimum co-financing	0.00	0.00
Recommended co-financing as per	0.00	0.00
Your co-financing	0.00	0.00

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#		144,500	219,600	169,200	192,600
Number of AD syringes	#		95,400	150,800	93,100	117,400
Number of re-constitution syringes	#		0	0	0	0
Number of safety boxes	#		1,050	2,425	1,875	2,125
Total value to be co-financed by GAVI	$		166,000	321,000	218,000	248,000

Table 7.11.2: Estimated GAVI support and country co-financing (**GAVI support**)

		2019	2020
Number of vaccine doses	#	162,000	174,600
Number of AD syringes	#	113,100	124,500
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	1,800	1,925
Total value to be co-financed by GAVI	$	184,500	199,000

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2014	2015	2016	2017	2018
Number of vaccine doses	#		0	0	0	0
Number of AD syringes	#		0	0	0	0
Number of re-constitution syringes	#		0	0	0	0
Number of safety boxes	#		0	0	0	0
Total value to be co-financed by the Country *[1]*	$		0	0	0	0

Table 7.11.3: Estimated GAVI support and country co-financing (**Country support**)

		2019	2020
Number of vaccine doses	#	0	0
Number of AD syringes	#	0	0
Number of re-constitution syringes	#	0	0
Number of safety boxes	#	0	0
Total value to be co-financed by the Country *[1]*	$	0	0

Table 7.11.4: Calculation of requirements for IPV, 10 dose(s) per vial, LIQUID (part 1)

		Formula	2014	2015		
				Total	Government	GAVI
A	**Country co-finance**	*V*				
B	**Number of children to be vaccinated with the second dose**	*Table 4*	0	77,017		
C	**Number of doses per child**	*Vaccine parameter (schedule)*	1	1		
D	**Number of doses needed**	*B x C*	0	77,018		
E	**Estimated vaccine wastage factor**	*Table 4*	1.00	2.00		
F	**Number of doses needed including wastage**	*D x E*		154,035		
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*				
H	**Stock to be deducted**	*H1 - 0.25 x F of previous year original approved*				
H1	**Calculated opening stock**	*H2 of previous year + I of previous year - F of previous year current estimation*				
H2	**Reported stock on January 1st**	*Table 7.11.1*	0	0		
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*		144,500		
J	**Number of doses per vial**	*Vaccine Parameter*				
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*				
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*				
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*				
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*				
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*				
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*				
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*				
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*				
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*				
T	**Total fund needed**	*(N+O+P+Q+R+S)*				
U	**Total country co-financing**	*I x country co-financing per dose (cc)*				
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*				

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for IPV, 10 dose(s) per vial, LIQUID (part 2)

		Formula	2016		
			Total	Government	GAVI
A	Country co-finance	*V*	0.00 %		
B	Number of children to be vaccinated with the second dose	*Table 4*	81,171	0	81,171
C	Number of doses per child	*Vaccine parameter (schedule)*	1		
D	Number of doses needed	*B x C*	81,171	0	81,171
E	Estimated vaccine wastage factor	*Table 4*	2.00		
F	Number of doses needed including wastage	*D x E*	162,342	0	162,342
G	Vaccines buffer stock	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	1,551	0	1,551
H	Stock to be deducted	*H1 - 0.25 x F of previous year original approved*	- 54,329	0	- 54,329
H1	Calculated opening stock	*H2 of previous year + I of previous year - F of previous year current estimation*	- 13,744	0	- 13,744
H2	Reported stock on January 1st	*Table 7.11.1*			
I	Total vaccine doses needed	*Round up((F + G - H) / vaccine package size) x vaccine package size*	219,600	0	219,600
J	Number of doses per vial	*Vaccine Parameter*	10		
K	Number of AD syringes (+ 10% wastage) needed	*(D + G – H) x 1.10*	150,757	0	150,757
L	Reconstitution syringes (+ 10% wastage) needed	*(I / J) x 1.10*	0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	*(I / 100) x 1.10*	2,416	0	2,416
N	Cost of vaccines needed	*I x vaccine price per dose (g)*	292,068	0	292,068
O	Cost of AD syringes needed	*K x AD syringe price per unit (ca)*	6,754	0	6,754
P	Cost of reconstitution syringes needed	*L x reconstitution price per unit (cr)*	0	0	0
Q	Cost of safety boxes needed	*M x safety box price per unit (cs)*	14	0	14
R	Freight cost for vaccines needed	*N x freight cost as of % of vaccines value (fv)*	21,906	0	21,906
S	Freight cost for devices needed	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	Total fund needed	*(N+O+P+Q+R+S)*	320,742	0	320,742
U	Total country co-financing	*I x country co-financing per dose (cc)*	0		
V	Country co-financing % of GAVI supported proportion	*U / (N + R)*	0.00 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for IPV, 10 dose(s) per vial, LIQUID (part 3)

		Formula	2017		
			Total	Government	GAVI
A	Country co-finance	*V*	0.00 %		
B	Number of children to be vaccinated with the second dose	*Table 4*	83,038	0	83,038
C	Number of doses per child	*Vaccine parameter (schedule)*	1		
D	Number of doses needed	*B x C*	83,038	0	83,038
E	Estimated vaccine wastage factor	*Table 4*	2.00		
F	Number of doses needed including wastage	*D x E*	166,076	0	166,076
G	Vaccines buffer stock	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	1,539	0	1,539
H	Stock to be deducted	*H1 - 0.25 x F of previous year original approved*			
H1	Calculated opening stock	*H2 of previous year + I of previous year - F of previous year current estimation*			
H2	Reported stock on January 1st	*Table 7.11.1*			
I	Total vaccine doses needed	*Round up((F + G - H) / vaccine package size) x vaccine package size*	169,200	0	169,200
J	Number of doses per vial	*Vaccine Parameter*	10		
K	Number of AD syringes (+ 10% wastage) needed	*(D + G – H) x 1.10*	93,035	0	93,035
L	Reconstitution syringes (+ 10% wastage) needed	*(I / J) x 1.10*	0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	*(I / 100) x 1.10*	1,862	0	1,862
N	Cost of vaccines needed	*I x vaccine price per dose (g)*	196,611	0	196,611
O	Cost of AD syringes needed	*K x AD syringe price per unit (ca)*	4,168	0	4,168
P	Cost of reconstitution syringes needed	*L x reconstitution price per unit (cr)*	0	0	0
Q	Cost of safety boxes needed	*M x safety box price per unit (cs)*	11	0	11
R	Freight cost for vaccines needed	*N x freight cost as of % of vaccines value (fv)*	16,909	0	16,909
S	Freight cost for devices needed	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	Total fund needed	*(N+O+P+Q+R+S)*	217,699	0	217,699
U	Total country co-financing	*I x country co-financing per dose (cc)*	0		
V	Country co-financing % of GAVI supported proportion	*U / (N + R)*	0.00 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for IPV, 10 dose(s) per vial, LIQUID (part 4)

		Formula	2018		
			Total	Government	GAVI
A	**Country co-finance**	*V*	0.00 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	84,948	0	84,948
C	**Number of doses per child**	*Vaccine parameter (schedule)*	1		
D	**Number of doses needed**	*B x C*	84,948	0	84,948
E	**Estimated vaccine wastage factor**	*Table 4*	2.00		
F	**Number of doses needed including wastage**	*D x E*	169,896	0	169,896
G	**Vaccines buffer stock**	***Buffer on doses needed*** + ***buffer on doses wasted*** ***Buffer on doses needed*** = *(D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** = *(F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	21,715	0	21,715
H	**Stock to be deducted**	*H1 - 0.25 x F of previous year original approved*			
H1	**Calculated opening stock**	*H2 of previous year + I of previous year - F of previous year current estimation*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	192,600	0	192,600
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	117,330	0	117,330
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	2,119	0	2,119
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	223,416	0	223,416
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	5,257	0	5,257
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	12	0	12
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	19,214	0	19,214
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	247,899	0	247,899
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	0		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	0.00 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for IPV, 10 dose(s) per vial, LIQUID (part 5)

		Formula	2019		
			Total	Government	GAVI
A	Country co-finance	*V*	0.00 %		
B	Number of children to be vaccinated with the second dose	*Table 4*	87,496	0	87,496
C	Number of doses per child	*Vaccine parameter (schedule)*	1		
D	Number of doses needed	*B x C*	87,496	0	87,496
E	Estimated vaccine wastage factor	*Table 4*	1.67		
F	Number of doses needed including wastage	*D x E*	146,119	0	146,119
G	Vaccines buffer stock	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	15,293	0	15,293
H	Stock to be deducted	*H1 - 0.25 x F of previous year original approved*			
H1	Calculated opening stock	*H2 of previous year + I of previous year - F of previous year current estimation*			
H2	Reported stock on January 1st	*Table 7.11.1*			
I	Total vaccine doses needed	*Round up((F + G - H) / vaccine package size) x vaccine package size*	162,000	0	162,000
J	Number of doses per vial	*Vaccine Parameter*	10		
K	Number of AD syringes (+ 10% wastage) needed	*(D + G – H) x 1.10*	113,068	0	113,068
L	Reconstitution syringes (+ 10% wastage) needed	*(I / J) x 1.10*	0	0	0
M	Total of safety boxes (+ 10% of extra need) needed	*(I / 100) x 1.10*	1,783	0	1,783
N	Cost of vaccines needed	*I x vaccine price per dose (g)*	163,134	0	163,134
O	Cost of AD syringes needed	*K x AD syringe price per unit (ca)*	5,066	0	5,066
P	Cost of reconstitution syringes needed	*L x reconstitution price per unit (cr)*	0	0	0
Q	Cost of safety boxes needed	*M x safety box price per unit (cs)*	10	0	10
R	Freight cost for vaccines needed	*N x freight cost as of % of vaccines value (fv)*	16,151	0	16,151
S	Freight cost for devices needed	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	Total fund needed	*(N+O+P+Q+R+S)*	184,361	0	184,361
U	Total country co-financing	*I x country co-financing per dose (cc)*	0		
V	Country co-financing % of GAVI supported proportion	*U / (N + R)*	0.00 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Table 7.11.4: Calculation of requirements for IPV, 10 dose(s) per vial, LIQUID (part 6)

		Formula	2020		
			Total	Government	GAVI
A	**Country co-finance**	*V*	0.00 %		
B	**Number of children to be vaccinated with the second dose**	*Table 4*	90,121	0	90,121
C	**Number of doses per child**	*Vaccine parameter (schedule)*	1		
D	**Number of doses needed**	*B x C*	90,121	0	90,121
E	**Estimated vaccine wastage factor**	*Table 4*	1.67		
F	**Number of doses needed including wastage**	*D x E*	150,503	0	150,503
G	**Vaccines buffer stock**	***Buffer on doses needed*** *+* ***buffer on doses wasted*** ***Buffer on doses needed*** *= (D - D of previous year original approved) x 0.25* ***Buffer on doses wasted*** *= (F - D) x [XXX] - ((F - D) of previous year current estimate) x 0.25*	22,970	0	22,970
H	**Stock to be deducted**	*H1 - 0.25 x F of previous year original approved*			
H1	**Calculated opening stock**	*H2 of previous year + I of previous year - F of previous year current estimation*			
H2	**Reported stock on January 1st**	*Table 7.11.1*			
I	**Total vaccine doses needed**	*Round up((F + G - H) / vaccine package size) x vaccine package size*	174,600	0	174,600
J	**Number of doses per vial**	*Vaccine Parameter*	10		
K	**Number of AD syringes (+ 10% wastage) needed**	*(D + G – H) x 1.10*	124,401	0	124,401
L	**Reconstitution syringes (+ 10% wastage) needed**	*(I / J) x 1.10*	0	0	0
M	**Total of safety boxes (+ 10% of extra need) needed**	*(I / 100) x 1.10*	1,921	0	1,921
N	**Cost of vaccines needed**	*I x vaccine price per dose (g)*	175,823	0	175,823
O	**Cost of AD syringes needed**	*K x AD syringe price per unit (ca)*	5,574	0	5,574
P	**Cost of reconstitution syringes needed**	*L x reconstitution price per unit (cr)*	0	0	0
Q	**Cost of safety boxes needed**	*M x safety box price per unit (cs)*	11	0	11
R	**Freight cost for vaccines needed**	*N x freight cost as of % of vaccines value (fv)*	17,407	0	17,407
S	**Freight cost for devices needed**	*(O+P+Q) x freight cost as % of devices value (fd)*	0	0	0
T	**Total fund needed**	*(N+O+P+Q+R+S)*	198,815	0	198,815
U	**Total country co-financing**	*I x country co-financing per dose (cc)*	0		
V	**Country co-financing % of GAVI supported proportion**	*U / (N + R)*	0.00 %		

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

Given that the shipment plan of 2014 is not yet available, the volume approved for 2014 is used as our best proxy of 2014 shipment. The information would be updated when the shipment plan will become available.

8. Health Systems Strengthening Support (HSS)

Instructions for reporting on HSS funds received

1. Please complete this section only if your country **was approved for and received HSS funds before or during January to December 2014**. All countries are expected to report on:

   a. Progress achieved in 2014

   b. HSS implementation during January – April 2015 (interim reporting)

   c. Plans for 2016

   d. Proposed changes to approved activities and budget (see No. 4 below)

For countries that received HSS funds within the last 3 months of 2014, or experienced other delays that limited implementation in 2014, this section can be used as an inception report to comment on start up activities.

2. In order to better align HSS support reporting to country processes, for countries of which the 2014 fiscal year starts in January 2014 and ends in December 2014, HSS reports should be received by the GAVI Alliance before **15th May 2015**. For other countries, HSS reports should be received by the GAVI Alliance approximately six months after the end of country fiscal year, e.g., if the country fiscal year ends in March 2015, the HSS reports are expected by GAVI Alliance by September 2015.

3. Please use your approved proposal as reference to fill in this Annual Progress Report. Please fill in this reporting template thoroughly and accurately and use additional space as necessary.

4. If you are proposing changes to approved objectives, activities and budget (reprogramming) please request the reprogramming guidelines by contacting your Country Responsible Officer at GAVI or by emailing gavihss@gavi.org.

5. If you are requesting a new tranche of funding, please make this clear in Section 8.1.2.

6. Please ensure that, **prior to its submission to the GAVI Alliance Secretariat, this report has been endorsed by the relevant country coordination mechanisms** (HSCC or equivalent) as provided for on the signature page in terms of its accuracy and validity of facts, figures and sources used.

7. Please attach all required supporting documents. These include:

   a. Minutes of all the HSCC meetings held in 2014

   b. Minutes of the HSCC meeting in 2015 that endorses the submission of this report

   c. Latest Health Sector Review Report

   d. Financial statement for the use of HSS funds in the 2014 calendar year

   e. External audit report for HSS funds during the most recent fiscal year (if available)

8. The GAVI Alliance Independent Review Committee (IRC) reviews all Annual Progress Reports. In addition to the information listed above, the IRC requires the following information to be included in this section in order to approve further tranches of HSS funding:

   a. Reporting on agreed indicators, as outlined in the approved M&E framework, proposal and approval letter;

   b. Demonstration of (with tangible evidence) strong links between activities, output, outcome and impact indicators;

   c. Outline of technical support that may be required to either support the implementation or monitoring of the GAVI HSS investment in the coming year

8. Inaccurate, incomplete or unsubstantiated reporting may lead the IRC to either send the APR back to your country for clarifications (which may cause delays in the release of further HSS funds), to recommend against the release of further HSS funds or only approve part of the next tranche of HSS funds.

8.1. Report on the use of HSS funds in 2014 and request of a new tranche

Please provide data sources for all data used in this report.

8.1.1. Report on the use of HSS funds in **2014**

Please complete Table 8.1.3.a and 8.1.3.b (as per APR) for each year of your country's approved multi-year HSS programme and both in US$ and local currency

Please note: If you are requesting a new tranche of funding, please make sure you fill in the last row of Table 8.1.3.a and 8.1.3.b.

8.1.2. Please indicate if you are requesting a new tranche of funding **No**

If yes, please indicate the amount of funding requested: US$

These funds should be sufficient to carry out HSS grant implementation through December 2016.

Table 8.1.3a (US)$

	2009	2010	2011	2012	2013	2014
Original annual budgets (*as per the originally approved HSS proposal*)						
Revised annual budgets (*if revised by previous Annual Progress Reviews*)						
Total funds received from GAVI during the calendar year (*A*)						
Remaining funds (carry over) from previous year (*B*)						
Total Funds available during the calendar year (*C=A+B*)						
Total expenditure during the calendar year (*D*)						
Balance carried forward to next calendar year (*E=C-D*)						
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]						

	2015	2016	2017	2018
Original annual budgets (*as per the originally approved HSS proposal*)				
Revised annual budgets (*if revised by previous Annual Progress Reviews*)				
Total funds received from GAVI during the				

calendar year (*A*)				
Remaining funds (carry over) from previous year (*B*)				
Total Funds available during the calendar year (*C=A+B*)				
Total expenditure during the calendar year (*D*)				
Balance carried forward to next calendar year (*E=C-D*)				
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]				

Table 8.1.3b (Local currency)

	2009	2010	2011	2012	2013	2014
Original annual budgets (*as per the originally approved HSS proposal*)						
Revised annual budgets (*if revised by previous Annual Progress Reviews*)						
Total funds received from GAVI during the calendar year (*A*)						
Remaining funds (carry over) from previous year (*B*)						
Total Funds available during the calendar year (*C=A+B*)						
Total expenditure during the calendar year (*D*)						
Balance carried forward to next calendar year (*E=C-D*)						
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]						

	2015	2016	2017	2018
Original annual budgets (*as per the originally approved HSS proposal*)				
Revised annual budgets (*if revised by previous Annual Progress Reviews*)				
Total funds received from GAVI during the calendar year (*A*)				
Remaining funds (carry over) from previous year (*B*)				
Total Funds available during the calendar year (*C=A+B*)				
Total expenditure during the calendar year (*D*)				
Balance carried forward to next calendar year (*E=C-D*)				
Amount of funding requested for future calendar year(s) [please ensure you complete this row if you are requesting a new tranche]				

Report of Exchange Rate Fluctuation

Please indicate in the table Table 8.3.c below the exchange rate used for each calendar year at opening and closing.

Table 8.1.3.c

Exchange Rate	2009	2010	2011	2012	2013	2014
Opening on 1 January						
Closing on 31 December						

Detailed expenditure of HSS funds during the 2014 calendar year

Please attach a detailed financial statement for the use of HSS funds during the 2014 calendar year *(Terms of reference for this financial statement are attached in the online APR Annexes)*. Financial statements should be signed by the Chief Accountant or by the Permanent Secretary of Ministry of Health. **(Document Number: 19)**

If any expenditures for the January April 2015 period are reported in Tables 8.1.3a and 8.1.3b, a separate, detailed financial statement for the use of these HSS funds must also be attached **(Document Number: 20)**

Has an external audit been conducted? Not selected

External audit reports for HSS programmes are due to the GAVI Secretariat six months following the close of your governments fiscal year. If an external audit report is available during your governments most recent fiscal year, this must also be attached (Document Number: 21)

8.2. Progress on HSS activities in the 2014 fiscal year

Please report on major activities conducted to strengthen immunisation using HSS funds in Table 8.2. It is very important to be precise about the extent of progress and use the M&E framework in your original

application and approval letter.

Please provide the following information for each planned activity:

- The percentage of activity completed where applicable
- An explanation about progress achieved and constraints, if any
- The source of information/data if relevant.

Table 8.2: HSS activities in the 2014 reporting year

Major Activities (insert as many rows as necessary)	**Planned Activity for 2014**	**Percentage of Activity completed (annual)** (where applicable)	**Source of information/data** (if relevant)

8.2.1 For each objective and activity (i.e. Objective 1, Activity 1.1, Activity 1.2, etc.), explain the progress achieved and relevant constraints (e.g. evaluations, HSCC meetings).

Major Activities (insert as many rows as necessary)	**Explain progress achieved and relevant constraints**

8.2.2 Explain why any activities have not been implemented, or have been modified, with references.

8.2.3 If GAVI HSS grant has been utilised to provide national health human resources incentives, how has the GAVI HSS grant been contributing to the implementation of national Human Resource policy or guidelines?

8.3. General overview of targets achieved

Please complete **Table 8.3** for each indicator and objective outlined in the original approved proposal and decision letter. Please use the baseline values and targets for 2013 from your original HSS proposal.

Table 8.3: Progress on targets achieved

Name of Objective or Indicator (Insert as many rows as necessary)	**Baseline**		**Agreed target till end of support in original HSS application**	**2014 Target**	**Data Source**	**Explanation if any targets were not achieved**
	Baseline value	**Baseline source/date**				

8.4. Programme implementation in 2014

8.4.1. Please provide a narrative on major accomplishments in 2014, especially impacts on health service programmes, and how the HSS funds benefited the immunisation programme

8.4.2. Please describe problems encountered and solutions found or proposed to improve future performance of HSS funds.

8.4.3. Please describe the exact arrangements at different levels for monitoring and evaluating GAVI funded HSS activities.

8.4.4. Please outline to what extent the M&E is integrated with country systems (such as, for example, annual sector reviews). Please describe ways in which reporting on GAVI HSS funds can be more organization with existing reporting systems in your country. This could include using the relevant indicators agreed in the sector-wide approach in place of GAVI indicators.

8.4.5. Please specify the participation of key stakeholders in the implementation of the HSS proposal

(including the EPI Programme and Civil Society Organisations). This should include organisation type, name and implementation function.

8.4.6. Please describe the participation of Civil Society Organisations in the implementation of the HSS proposal. Please provide names of organisations, type of activities and funding provided to these organisations from the HSS funding.

8.4.7. Please describe the management of HSS funds and include the following:

- Whether the management of HSS funds has been effective
- Constraints to internal fund disbursement, if any
- Actions taken to address any issues and to improve management
- Any changes to management processes in the coming year

8.5. Planned HSS activities for 2015

Please use **Table 8.5** to provide information on progress on activities in 2015. If you are proposing changes to your activities and budget in 2015 please explain these changes in the table below and provide explanations for these changes.

Table 8.5: Planned activities for 2015

Major Activities (insert as many rows as necessary)	**Planned Activity for 2015**	**Original budget for 2015** (as approved in the HSS proposal or as adjusted during past annual progress reviews)	**2015 actual expenditure** (as at April 2015)	**Revised activity** (if relevant)	**Explanation for proposed changes to activities or budget** (if relevant)	**Revised budget for 2015** (if relevant)
		0	0			0

8.6. Planned HSS activities for 2016

Please use **Table 8.6** to outline planned activities for 2016. If you are proposing changes to your activities and budget please explain these changes in the table below and provide explanations for each change so that the IRC can recommend for approval the revised budget and activities.

Please note that if the change in budget is greater than 15% of the approved allocation for the specific activity in that financial year, these proposed changes must be submitted for IRC approval with the evidence for requested changes

Table 8.6: Planned HSS Activities for 2016

Major Activities (insert as many rows as necessary)	**Planned Activity for 2016**	**Original budget for 2016** (as approved in the HSS proposal or as adjusted during past annual progress reviews)	**Revised activity** (if relevant)	**Explanation for proposed changes to activities or budget** (if relevant)	**Revised budget for 2016** (if relevant)
		0			

8.7. Revised indicators in case of reprogramming

Countries planning to submit reprogramming requests may do so any time of the year. Please request the reprogramming guidelines by contacting your Country Responsible Officer at GAVI or by emailing gavihss@gavi.org

8.8. Other sources of funding for HSS

If other donors are contributing to the achievement of the country's objectives as outlined in the GAVI HSS proposal, please outline the amount and links to inputs being reported on:

Table 8.8: Sources of HSS funds in your country

Donor	Amount in US$	Duration of support	Type of activities funded

8.8.1. Is GAVI's HSS support reported on the national health sector budget? **Not selected**

8.9. Reporting on the HSS grant

8.9.1. Please list the **main** sources of information used in this HSS report and outline the following:

- How information was validated at country level prior to its submission to the GAVI Alliance.
- Any important issues raised in terms of accuracy or validity of information (especially financial information and the values of indicators) and how these were dealt with or resolved.

Table 8.9.1: Data sources

Data sources used in this report	How information was validated	Problems experienced, if any

8.9.2. Please describe any difficulties experienced in putting this report together that you would like the GAVI Alliance and IRC to be aware of. This information will be used to improve the reporting process.

8.9.3. How many times did the Health Sector Coordinating Committee (HSCC) meet in 2014?

Please attach:

1. The minutes from the HSCC meetings in 2015 endorsing this report **(Document Number: 6)**
2. The latest Health Sector Review report **(Document Number: 22)**

9. Strengthened Involvement of Civil Society Organisations (CSOs) : Type A and Type B

9.1. TYPE A: Support to strengthen coordination and representation of CSOs

Gambia **has NOT received GAVI TYPE A CSO support**

Gambia is not reporting on GAVI TYPE A CSO support for 2014

9.2. TYPE B: Support for CSOs to help implement the GAVI HSS proposal or cMYP

Gambia **has NOT received GAVI TYPE B CSO support**

Gambia is not reporting on GAVI TYPE B CSO support for 2014

10. Comments from ICC/HSCC Chairs

Please provide any comments that you may wish to bring to the attention of the monitoring IRC in the course of this review and any information you may wish to share in relation to challenges you have experienced during the year under review. These could be in addition to the approved minutes, which should be included in the attachments

11. Annexes

11.1. Annex 1 – Terms of reference ISS

TERMS OF REFERENCE:

FINANCIAL STATEMENTS **FOR IMMUNISATION SERVICES SUPPORT (ISS)** AND **NEW VACCINE INTRODUCTION GRANTS**

I. All countries that have received ISS /new vaccine introduction grants during the 2014 calendar year, or had balances of funding remaining from previously disbursed ISS/new vaccine introduction grants in 2014, are required to submit financial statements for these programmes as part of their Annual Progress Reports.

II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.

III. **At a minimum**, GAVI requires a simple statement of income and expenditure for activity during the 2014 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on the next page.

a. Funds carried forward from the 2013 calendar year (opening balance as of 1 January 2014)

b. Income received from GAVI during 2014

c. Other income received during 2014 (interest, fees, etc)

d. Total expenditure during the calendar year

e. Closing balance as of 31 December 2014

f. A detailed analysis of expenditures during 2014, based on ***your government's own system of economic classification.*** This analysis should summarise total annual expenditure for the year by your government's own system of economic classification, and relevant cost categories, for example: wages & salaries. If possible, please report on the budget for each category at the beginning of the calendar year, actual expenditure during the calendar year, and the balance remaining for each cost category as of 31 December 2014 (referred to as the "variance").

IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.

V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2014 financial year. Audits for ISS are due to the GAVI Secretariat 6 months following the close of each country's financial year.

11.2. Annex 2 – Example income & expenditure ISS

MINIMUM REQUIREMENTS FOR **ISS** AND VACCINE INTRODUCTION GRANT FINANCIAL STATEMENTS *1*

An example statement of income & expenditure

Summary of income and expenditure – GAVI ISS		
	Local currency (CFA)	**Value in USD ***
Balance brought forward from 2013 (balance as of *31Decembre 2013*)	25,392,830	53,000
Summary of income received during 2014		
Income received from GAVI	57,493,200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2014	30,592,132	63,852
Balance as of 31 December 2014 (balance carried forward to 2015)	60,139,325	125,523

* Indicate the exchange rate at opening 01.01.2014, the exchange rate at closing 31.12.2014, and also indicate the exchange rate used for the conversion of local currency to US$ in these financial statements.

Detailed analysis of expenditure by economic classification ** – GAVI ISS						
	Budget in CFA	**Budget in USD**	**Actual in CFA**	**Actual in USD**	**Variance in CFA**	**Variance in USD**
Salary expenditure						
Wedges & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12,650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4,000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1,000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2014	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

11.3. Annex 3 – Terms of reference HSS

TERMS OF REFERENCE:

FINANCIAL STATEMENTS FOR **HEALTH SYSTEMS STRENGTHENING (HSS)**

I. All countries that have received HSS grants during the 2014 calendar year, or had balances of funding remaining from previously disbursed HSS grants in 2014, are required to submit financial statements for these programmes as part of their Annual Progress Reports.

II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.

III. At a minimum, GAVI requires a simple statement of income and expenditure for activity during the 2014 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on the next page.

a. Funds carried forward from the 2013 calendar year (opening balance as of 1 January 2014)

b. Income received from GAVI during 2014

c. Other income received during 2014 (interest, fees, etc)

d. Total expenditure during the calendar year

e. Closing balance as of 31 December 2014

f. A detailed analysis of expenditures during 2014, based on your government's own system of economic classification. This analysis should summarise total annual expenditure for each HSS objective and activity, per your government's originally approved HSS proposal, with further breakdown by cost category (for example: wages & salaries). Cost categories used should be based upon your government's own system for economic classification. Please report the budget for each objective, activity and cost category at the beginning of the calendar year, the actual expenditure during the calendar year, and the balance remaining for each objective, activity and cost category as of 31 December 2014 (referred to as the "variance").

IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.

V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2014 financial year. Audits for HSS are due to the GAVI Secretariat 6 months following the close of each country's financial year.

11.4. Annex 4 – Example income & expenditure HSS

MINIMUM REQUIREMENTS FOR **HSS** FINANCIAL STATEMENTS:

An example statement of income & expenditure

Summary of income and expenditure – GAVI HSS		
	Local currency (CFA)	**Value in USD ***
Balance brought forward from 2013 (balance as of *31Decembre 2013*)	25,392,830	53,000
Summary of income received during 2014		
Income received from GAVI	57,493,200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2014	30,592,132	63,852
Balance as of 31 December 2014 (balance carried forward to 2015)	60,139,325	125,523

* Indicate the exchange rate at opening 01.01.2014, the exchange rate at closing 31.12.2014, and also indicate the exchange rate used for the conversion of local currency to US$ in these financial statements.

Detailed analysis of expenditure by economic classification ** - GAVI HSS						
	Budget in CFA	**Budget in USD**	**Actual in CFA**	**Actual in USD**	**Variance in CFA**	**Variance in USD**
Salary expenditure						
Wedges & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12,650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4,000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1,000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2014	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

11.5. Annex 5 – Terms of reference CSO

TERMS OF REFERENCE:

FINANCIAL STATEMENTS FOR **CIVIL SOCIETY ORGANISATION (CSO)** TYPE B

I. All countries that have received CSO 'Type B' grants during the 2014 calendar year, or had balances of funding remaining from previously disbursed CSO 'Type B' grants in 2014, are required to submit financial statements for these programmes as part of their Annual Progress Reports.

II. Financial statements should be compiled based upon countries' own national standards for accounting, thus GAVI will not provide a single template to countries with pre-determined cost categories.

III. At a minimum, GAVI requires a simple statement of income and expenditure for activity during the 2014 calendar year, to be comprised of points (a) through (f), below. A sample basic statement of income and expenditure is provided on page 3 of this annex.

a. Funds carried forward from the 2013 calendar year (opening balance as of 1 January 2014)

b. Income received from GAVI during 2014

c. Other income received during 2014 (interest, fees, etc)

d. Total expenditure during the calendar year

e. Closing balance as of 31 December 2014

f. A detailed analysis of expenditures during 2014, based on your government's own system of economic classification. This analysis should summarise total annual expenditure by each civil society partner, per your government's originally approved CSO 'Type B' proposal, with further breakdown by cost category (for example: wages & salaries). Cost categories used should be based upon your government's own system for economic classification. Please report the budget for each objective, activity and cost category at the beginning of the calendar year, the actual expenditure during the calendar year, and the balance remaining for each objective, activity and cost category as of 31 December 2014 (referred to as the "variance").

IV. Financial statements should be compiled in local currency, with an indication of the USD exchange rate applied. Countries should provide additional explanation of how and why a particular rate of exchange has been applied, and any supplementary notes that may help the GAVI Alliance in its review of the financial statements.

V. Financial statements need not have been audited/certified prior to their submission to GAVI. However, it is understood that these statements should be subjected to scrutiny during each country's external audit for the 2014 financial year. Audits for CSO 'Type B' are due to the GAVI Secretariat 6 months following the close of each country's financial year.

11.6. Annex 6 – Example income & expenditure CSO

MINIMUM REQUIREMENTS FOR **CSO 'Type B'** FINANCIAL STATEMENTS

An example statement of income & expenditure

Summary of income and expenditure – GAVI CSO		
	Local currency (CFA)	**Value in USD ***
Balance brought forward from 2013 (balance as of *31Decembre 2013*)	25,392,830	53,000
Summary of income received during 2014		
Income received from GAVI	57,493,200	120,000
Income from interest	7,665,760	16,000
Other income (fees)	179,666	375
Total Income	38,987,576	81,375
Total expenditure during 2014	30,592,132	63,852
Balance as of 31 December 2014 (balance carried forward to 2015)	60,139,325	125,523

* Indicate the exchange rate at opening 01.01.2014, the exchange rate at closing 31.12.2014, and also indicate the exchange rate used for the conversion of local currency to US$ in these financial statements.

Detailed analysis of expenditure by economic classification ** - GAVI CSO						
	Budget in CFA	**Budget in USD**	**Actual in CFA**	**Actual in USD**	**Variance in CFA**	**Variance in USD**
Salary expenditure						
Wedges & salaries	2,000,000	4,174	0	0	2,000,000	4,174
Per diem payments	9,000,000	18,785	6,150,000	12,836	2,850,000	5,949
Non-salary expenditure						
Training	13,000,000	27,134	12,650,000	26,403	350,000	731
Fuel	3,000,000	6,262	4,000,000	8,349	-1,000,000	-2,087
Maintenance & overheads	2,500,000	5,218	1,000,000	2,087	1,500,000	3,131
Other expenditures						
Vehicles	12,500,000	26,090	6,792,132	14,177	5,707,868	11,913
TOTALS FOR 2014	42,000,000	87,663	30,592,132	63,852	11,407,868	23,811

** Expenditure categories are indicative and only included for demonstration purpose. Each implementing government should provide statements in accordance with its own system for economic classification.

12. Attachments

Document Number	Document	Section	Mandatory	File
1	Signature of Minister of Health (or delegated authority)	2.1	✓	APR Signatures.pdf **File desc:** **Date/time :** 30/04/2015 07:45:05 **Size:** 385 KB
2	Signature of Minister of Finance (or delegated authority)	2.1	✓	APR Signatures.pdf **File desc:** **Date/time :** 30/04/2015 07:45:11 **Size:** 385 KB
3	Signatures of members of ICC	2.2	✓	ICC Signatures.pdf **File desc:** **Date/time :** 30/04/2015 02:07:17 **Size:** 1 MB
4	Minutes of ICC meeting in 2015 endorsing the APR 2014	5.4	✓	April 2015 ICC Meeting-final.docx **File desc:** **Date/time :** 30/04/2015 09:59:43 **Size:** 44 KB
5	Signatures of members of HSCC	2.3	✓	ICC Signatures.pdf **File desc:** **Date/time :** 30/04/2015 02:08:10 **Size:** 1 MB
6	Minutes of HSCC meeting in 2015 endorsing the APR 2014	8.9.3	✓	April 2015 ICC Meeting-final.doc **File desc:** **Date/time :** 30/04/2015 02:10:15 **Size:** 87 KB
7	Financial statement for ISS grant (Fiscal year 2014) signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	6.2.1	✗	No file loaded
8	External audit report for ISS grant (Fiscal Year 2014)	6.2.3	✗	No file loaded
9	Post Introduction Evaluation Report	7.2.1	✗	No file loaded

10	Financial statement for NVS introduction grant (Fiscal year 2014) signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	7.3.1	✓	NO NVS INTRODUCTION GRANT.doc **File desc:** **Date/time :** 30/04/2015 08:49:38 **Size:** 28 KB
11	External audit report for NVS introduction grant (Fiscal year 2014) if total expenditures in 2014 is greater than US$ 250,000	7.3.1	✓	NO NVS INTRODUCTION GRANT.doc **File desc:** **Date/time :** 30/04/2015 08:52:01 **Size:** 28 KB
12	Latest EVSM/VMA/EVM report	7.5	✓	GAM EVMA 2014 Report Final.doc **File desc:** **Date/time :** 30/04/2015 08:15:37 **Size:** 3 MB
13	Latest EVSM/VMA/EVM improvement plan	7.5	✓	GAM EVM IMPROVEMENT PLAN 2014.xls **File desc:** **Date/time :** 30/04/2015 08:27:13 **Size:** 217 KB
14	EVSM/VMA/EVM improvement plan implementation status	7.5	✓	GAM EVM IMPROVEMENT PLAN 2014_STATUS OF IMPLEMENTATION.xls **File desc:** **Date/time :** 30/04/2015 02:16:31 **Size:** 218 KB
16	Valid cMYP if requesting extension of support	7.8	✓	THE GAMBIA cMYP FOR 2012-2016_Latest_30.04.2015.doc **File desc:** **Date/time :** 30/04/2015 08:28:57 **Size:** 546 KB
17	Valid cMYP costing tool if requesting extension of support	7.8	✓	The Gambia_cMYP_Costing_Tool_2012-2016_Latest.30.04.2015.xls **File desc:** **Date/time :** 30/04/2015 08:34:55 **Size:** 3 MB
18	Minutes of ICC meeting endorsing extension of vaccine support if applicable	7.8	✓	April 2015 ICC Meeting-final.docx **File desc:** **Date/time :** 30/04/2015 09:55:17 **Size:** 44 KB
19	Financial statement for HSS grant (Fiscal year 2014) signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	8.1.3	✓	NO HSS FINANCIAL STATEMENT.doc **File desc:** **Date/time :** 30/04/2015 09:12:08 **Size:** 28 KB

20	Financial statement for HSS grant for January-April 2015 signed by the Chief Accountant or Permanent Secretary in the Ministry of Health	8.1.3	✓	NO HSS FINANCIAL STATEMENT.doc **File desc:** **Date/time :** 30/04/2015 09:16:02 **Size:** 28 KB
21	External audit report for HSS grant (Fiscal Year 2014)	8.1.3	✓	NO HSS EXTERNAL AUDIT.doc **File desc:** **Date/time :** 30/04/2015 09:17:52 **Size:** 28 KB
22	HSS Health Sector review report	8.9.3	✓	NO HSS HEALTH SECTOR REVIEW.doc **File desc:** **Date/time :** 30/04/2015 08:44:10 **Size:** 28 KB
23	Report for Mapping Exercise CSO Type A	9.1.1	✗	No file loaded
24	Financial statement for CSO Type B grant (Fiscal year 2014)	9.2.4	✗	No file loaded
25	External audit report for CSO Type B (Fiscal Year 2014)	9.2.4	✗	No file loaded
26	Bank statements for each cash programme or consolidated bank statements for all existing cash programmes if funds are comingled in the same bank account, showing the opening and closing balance for year 2014 on (i) 1st January 2014 and (ii) 31st December 2014	0	✓	NO NVS INTRODUCTION GRANT.doc **File desc:** **Date/time :** 30/04/2015 09:10:36 **Size:** 24 KB
27	Minutes ICC meeting endorsing change of vaccine prensentation	7.7	✗	No file loaded
28	Justification for changes in target population	5.1	✗	No file loaded

	Other		✕	No file loaded